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CHAPTER I 
 
 
 
INTRODUCTION 
 
Objective of Dissertation 
As atherosclerotic lesions develop, foam cells in the lesion accumulate significant 
amounts of cholesterol in large, swollen lysosomes. Previous studies from our 
laboratory and others using macrophages in culture indicate that cholesterol derived 
from various cholesteryl ester (CE) sources can mimic this lysosomal accumulation (1-
11).  Early in atherosclerosis, free cholesterol (FC) is the primary form of cholesterol in 
lysosomes. However, in later stages, both FC and CE are found trapped in the lysosome 
(9,12). The late-stage CE accumulation is the result of an inhibition of lysosomal CE 
hydrolysis (9-11,13). Lysosomal acid lipase (LAL) is the principal enzyme responsible for 
lysosomal CE hydrolysis. During CE accumulation, there is a concomitant increase in the 
lysosome pH to a level that is not conducive to LAL activity. This suggests an inverse 
correlation between lysosomal pH and inhibition of CE hydrolysis.  
Cholesterol is trapped within lipid engorged lysosomes. Stimulation of 
cholesterol efflux removes extralysosomal cholesterol but does not reduce the 
lysosomal FC and CE stores. However, preliminary studies in our laboratory showed that 
triglyceride-rich particles (TRPs), similar to those present in the atherosclerotic lesion, 
have the potential to influence lysosomal and cellular cholesterol metabolism and 
homeostasis.  Based on our preliminary studies and literature suggesting a role of 
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triglyceride (TG) in macrophage foam cell cholesterol homeostasis, we hypothesized 
that TG-treatment might enhance CE hydrolysis and FC clearance from lysosomes. One 
mechanism by which this could occur is by helping lysosomes maintain a low pH and, 
thus, continue CE hydrolysis. It is also possible that TG treatment might enhance the 
expression of proteins important in cholesterol metabolism. The objective of this 
research was to test these hypotheses by investigating the effect of TRP-treatment on 
lysosomal pH, lysosomal CE hydrolysis, and lysosomal and cellular sterol clearance.   
We divided the work into three separate, but related, aims. The first aim was to 
determine the effect of TG treatment on the lysosomal degradation of CE and 
mobilization of FC from lysosomes.  Preliminary results indicated that cellular 
cholesterol levels were reduced when treated with TG. Therefore, we sought to 
investigate the enhancement of lysosomal CE hydrolysis as a potential mechanism for 
this reduction in cellular cholesterol levels. We employed biochemical and microscopic 
analyses to examine the cellular and lysosomal hydrolysis of CE and subsequent 
clearance of FC within the lysosome in cells treated with TG and/or CE-rich lipid 
particles. 
The second aim was to determine the effects of TG treatment on lysosomal 
acidification. Initial studies suggested that lysosome activity is maintained upon 
treatment with TRPs, even in the presence of CE-rich vehicles.  Given our data indicating 
a relationship of CE hydrolysis rate and lysosome pH, we sought to determine if TG 
acted to reestablish normal acidic lysosome pH. Studies were performed to measure 
lysosomal pH in cells treated with TG and/or CE-rich lipid particles.  Additionally, in 
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order to define the mechanism of the effects of TRPs on lysosomal acidification, 
biochemical analyses were performed to examine the activity of the lysosomal vacuolar-
type H+-ATPase (v-ATPase), a critical proton pump responsible for maintaining acidic 
lysosomal pH.  We also examined lysosome membrane order in the presence of 
cholesterol accumulation and after TRP treatment. Membrane order is a known 
regulator of many membrane proteins (14,15) and, thus, is a possible mediator of the 
cholesterol and TG effects on lysosomal function.   
Our third aim was to determine whether TG hydrolysis was necessary for TRP to 
affect lysososmal CE metabolism. As described above, preliminary studies showed 
enhanced cholesterol clearance and improved lysosomal activity within macrophage 
foam cells treated with TRPs.  As part of this goal, it was important to differentiate 
between lysosomal TG, cytoplasmic TG and/or hydrolytically released fatty acids (FAs) as 
the mediator of enhanced cholesterol clearance from the lysosome. Biochemical 
analyses were used to determine if TG and/or hydrolytically released FAs are required 
for lysosomal and cholesterol homeostatic effects. Additionally, studies examined the 
potential for TG to mobilize cellular cholesterol by investigating the regulation of 
cholesterol efflux pathways following TG enrichment.   
Cholesterol is an important molecule that influences both structural and 
functional properties of all membranes and lysosomal cholesterol accumulation is a 
common attribute of foam cells in atherosclerotic lesions. It is also a major homeostatic 
signal. The sequestration of cholesterol (both FC and CE) in lysosomes, away from 
normal cellular sterol metabolic pathways, could have dramatic effects on a number of 
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cell properties and might lead to cells that are substantially more proatherogenic than 
foam cells without lysosomal sequestration. Thus, understanding intracellular 
cholesterol metabolism and the influences of cholesterol sequestration or release on 
other metabolic pathways are critical to understanding atherosclerosis. To date, most 
studies of cellular cholesterol accumulation and its effects deal with cells in which 
cholesterol is the principal lipid being metabolized. However, in atherosclerotic lesions 
there are a number of TG-rich sources of lipid that can be taken up by foam cells. Our 
data suggest that TRPs can influence lysosomal cholesterol metabolism and, thus, have 
consequences for atherogenesis. The studies described in this dissertation have 
improved our understanding of the nature of the TRP and cholesterol interactions 
within the lysosomes and the subsequent effects on macrophage foam cells. 
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CHAPTER II 
 
BACKGROUND AND SIGNIFICANCE 
 
Pathogenesis of Atherosclerosis 
Atherosclerosis is a complex disease, with multiple factors contributing to its 
pathogenesis. It is an insidious disease that begins in early childhood and develops over 
a lifetime, but clinical complications typically become manifest in late adulthood (16,17). 
Genetic and epidemiologic factors contributing to the development of atherosclerosis 
are the key to how fast lesions advance to clinical stages. Genetic risk factors, including 
lipid abnormalities, hypertension, diabetes, and obesity can speed the progression (17-
19). Overlying the genetic factors, a number of environmental factors, including 
smoking, unhealthy diet, and lack of physical activity also contribute to the progression 
of lesions (17-19). While conventional risk factors determine the time course of lesion 
development, importantly, the latency of clinical disease onset provides an extended 
period of time for therapeutic intervention. However, in order to develop effective 
therapies, it is important to define the key factors involved in atherogenesis. 
 
Early Atherosclerotic Lesions 
Early atherosclerotic lesions are characteristically cellular in nature. Although the 
initiating factors are still debated, it is believed that one of the earliest events in 
atherogenesis is endothelial cell dysfunction, which initiates the recruitment of 
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circulating monocytes to the arterial endothelium. Endothelial dysfunction is thought to 
result from vessel injury, an increase in lipid deposition in the subendothelial space, 
and/or changes in shear stress within the vasculature (20-22). Monocytes are recruited 
to the endothelium as part of a normal inflammatory response to endothelial cell 
damage as well as in response to chemoattractants released from the artery wall, such 
as monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8) (23-28). 
Recruitment includes upregulation of adhesion molecules on both monocytes and 
activated arterial endothelial cells (29-32). Monocyte adhesion molecules include β2-
integrin, VLA-4, and PCAM-1 while endothelial cells express the adhesion molecules P-
selectin, E-selectin, VCAM-1 and ICAM-1. Following adherence, the monocytes 
transmigrate into the arterial wall (figure 1). Once inside the subendothelial space, 
monocytes differentiate into macrophages.  The infiltration and accumulation of 
macrophages in the artery wall are the hallmarks of early atherosclerotic lesions (figures 
1 and 2).  This process is known as the “response-to-injury” hypothesis of 
atherosclerosis (33). 
 
Intermediate Atherosclerotic Lesions 
As lesions progress to fatty streaks, lipids play a significant role in lesion 
advancement. Intermediate atherosclerotic lesion growth occurs primarily by the 
accumulation of lipid in the subendothelial space.  Lipoproteins present in circulation 
are able to pass into the arterial intima. Once in the artery wall, the cholesterol-rich 
lipoproteins, primarily low-density lipoproteins (LDLs), are subject to modification, 
including oxidation and aggregation (figure 2)(34,35). While the recruitment of 
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Figure 1: Atherosclerosis is a progressive disease, involving a number of cell types and 
lipids. Lesions at various stages are classified based on their histology.  The progression 
of early lesion development (initial lesions, fatty streaks, intermediate lesions and 
atheroma) are predominantly driven by lipid accumulation in the artery wall and in lipid-
enriched macrophage foam cells.  Clinical manifestations become present at late-stage 
lesions (fibroatheroma and complicated lesions).  Growth of late stage lesions occurs by 
the infiltration of smooth muscle cells and collagen into the artery wall. Complicated 
lesions may become unstable, leading to rupture, hemorrhage and thrombosis. Such 
complications result in clinical ailments, including myocardial infarction and stroke. 
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Figure 2: Monocyte-derived macrophages and circulating lipoproteins play predominant 
roles in atherosclerotic lesion development. The earliest events in atheroma formation 
include endothelial dysfunction and lipid accumulation in the arterial intima.  This 
results in the recruitment of monocytes to the arterial endothelium.  Monocytes 
migrate into the subendothelial space and differentiate into macrophages.  Following 
differentiation, macrophages ingest large amounts of modified lipoproteins present in 
the subendothelial space resulting in the formation of macrophage foam cells. 
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monocytes/macrophages is initially a protective immune response to arterial injury, 
uptake of modified LDL via macrophage scavenger receptor-mediated endocytosis, and 
possibly other mechanisms, leads to macrophage foam cell formation.  Foam cells, 
named for the “foamy” appearance created by the severe lipid accumulation, are 
macrophages that have engulfed large amounts of lipid. Foam cells are a hallmark of the 
thickened atherosclerotic lesion.  Progressive accumulation of modified LDLs in the 
artery wall and continual formation of foam cells leads to intermediate lesions and 
atheroma (figure 1).  During the intermediate stages of atherosclerosis, a core of 
extracellular lipid develops and grows.  The progressive accumulation of lipid and 
cellular material leads to more advanced and more unstable atherosclerotic lesions. 
 
Late Atherosclerotic Lesions 
Late stage lesions are far more complicated than earlier stages of atherosclerosis 
and, with the increased degree of complexity, clinical complications become manifest.  
Atherosclerosis remains largely asymptomatic unless the lesion is sufficient to obstruct 
blood flow in the artery. In these cases, exertion can produce angina due to insufficient 
blood flow.  These larger, late stage lesions include more than just monocyte-derived 
macrophage foam cells and extracellular lipid.  Smooth muscle cells are recruited to the 
lesion from the underlying medial portion of the artery wall. There is also a concomitant 
increase in collagen that is secreted from SMCs (36,37).  All of these events contribute 
to arterial wall thickening. At even later stages, the lesion can become fibrotic and/or 
calcified, which leads to the advancement to complicated, clinically important lesions 
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(38-40). Complicated lesions often contain a core of necrotic material (17).  The necrotic 
core consists of dead and dying macrophages, macrophage debris and extracellular lipid, 
including cholesterol crystals (41-46).  The size of the necrotic core renders advanced 
lesions highly unstable and, as a result, they are subject to hemorrhage and thrombosis 
(45).  The rupture of unstable, advanced lesions results in myocardial infarction and 
stroke, two of the most common clinical manifestations of atherosclerosis and the most 
common causes of death from atherosclerosis (47-49).   
 
Therapeutic Intervention during the Progression of Atherosclerosis 
Atherosclerotic lesions develop over a period of decades. Hence, there is 
sufficient time for intervention if the lesions are detected. Unfortunately, in the majority 
of cases, atherosclerosis remains undetected until the presentation of late-stage, clinical 
lesions.  Therefore, the development of therapies to remedy late-stage atherosclerosis 
is important. Current options for treatment reduce or eliminate exposure to risk factors 
but do not cure the disease. Therapies include restriction of dietary fat and cholesterol, 
pharmacologic interventions, aerobic exercise, and, in more severe cases, surgical 
intervention to place stents in the affected artery or to completely remove portions of 
occluded arteries.  While these therapies will slow lesion progression or protect against 
rupture, they do not permanently resolve advanced lesions. Therefore, the 
identification of therapies that will promote lesion regression is most significant in 
treating clinical atherosclerosis. Recent studies in the literature identify macrophage 
foam cells as important targets for inducing atherosclerotic lesion regression (50,51).  
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Specifically, reducing the lipid content of macrophage foam cells in vivo can significantly 
reduce lesion area and, perhaps, help stabilize the plaque.  Thus, defining mediators of 
intracellular cholesterol homeostasis that can be manipulated to treat advanced 
atherosclerotic lesions is an important therapeutic target. 
 
Dietary Lipids in Physiology 
Dietary lipids, including cholesterol and TG, are significant to normal physiology. 
Cholesterol is an important component of cellular membranes and steroid hormones 
while TG provides a significant amount of energy required for cellular function. For 
transportation in the blood and lymph system, cholesterol and TG are packaged into 
macromolecular complexes of proteins and lipid called lipoproteins. Lipoproteins can be 
classified based on their hydrated density into five major classes: chylomicrons (CMs), 
very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-
density lipoproteins (LDL), and high-density lipoproteins (HDL). Additionally, lipoproteins 
are defined by their lipid and apoprotein composition (table 1). Importantly, 
apoproteins maintain the solubility of lipid-rich particles in the aqueous environment of 
the plasma, transport and redistribute lipids among various tissues, function as ligands 
in the receptor-mediated uptake of lipoproteins, maintain the structure of the 
lipoproteins, and function as cofactors for enzymes of lipid metabolism (52-55).  The 
production, circulation, and metabolism of circulating lipoproteins are important in 
normal metabolism and in several pathological conditions, including atherosclerosis. 
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Table 1: Composition of the major classes of lipoproteins. 
 
 
Class Density 
(g/ml) 
Diameter 
(nm) 
Lipid Content Apoprotein Content 
   % CE % PL % TG % Protein Apoproteins 
CMs 
 
<0.95 100 – 1000 8 7 84 <2 apoAIV, apoB48, 
apoCI, apoCII, 
apoCIII 
VLDL 0.95 – 1.006 30 – 80 22 18 50 10 apoB100, apoE, 
apoCI, apoCII, 
apoCIII 
IDL 1.006 – 1.019 25 – 50 29 22 31 18 apoB100, apoE 
LDL 1.019 – 1.063 18 – 28 50 21 4 25 apoB100 
HDL >1.063 5 – 15 30 29 8 33 apoAI, apoAII, 
apoAV, apoD, 
apoE 
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Systemic Dietary Lipid Homeostasis 
Cholesterol and TG are derived from consumption of animal products and 
saturated fats and/or synthesized within cells.  Following a meal, dietary lipids are 
absorbed in the intestine, packaged into chylomicrons and secreted into the lymphatic 
system (figure 3). These TRPs deliver TG to peripheral tissues, including adipose and 
skeletal muscle, for storage or oxidation, respectively.  Additionally, whole or remnant 
CMs deliver lipids to hepatocytes, where dietary and synthesized lipids are assembled 
into VLDL. After assembly in hepatocytes, VLDL enters the circulation and transfers lipids 
to extrahepatic tissues, where TG is utilized for cellular energy. However, in the 
circulation, VLDL undergoes extensive remodeling, which alters the lipid and apoprotein 
content of the lipoproteins. Specifically, VLDL TGs are degraded by lipases, including 
lipoprotein lipase (LPL) and hepatic lipase (HL), resulting in the production of IDL, and 
eventually LDL, the lipoprotein responsible for transferring cholesterol to peripheral 
tissues (figure 3). Furthermore, complex interactions between lipoproteins in circulation 
can alter their lipid and apoprotein composition.  For example, HDL can transfer 
apoproteins to VLDL through aqueous diffusion and can exchange lipids with VLDL by 
the activity of phospholipid transfer protein (PLTP) and cholesterol ester transfer 
protein (CETP) (56,57). Despite the complexity of the interactions between circulating 
lipoproteins, it is important to note that all of the aforementioned lipoproteins are 
present in the circulation and the periphery, including within atherosclerotic lesions.  
The exposure of peripheral cells to circulating lipoproteins is important in normal and 
pathological conditions, including atherosclerosis. 
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Figure 3: Systemic lipoprotein metabolism. Following a meal, lipids are absorbed in the 
intestine and packaged into CMs.  Hydrolysis of CM-TG in the circulation results in the 
formation of CM remnants (CMRs). CMRs are delivered to the liver where dietary lipids 
carried by the CMRs and lipids synthesized by hepatocytes are assembled into VLDL.  
VLDL enters the circulation and sequential hydrolysis of VLDL-TG results in the formation 
of IDL and LDL. HDL is also present in the circulation and can interact with other 
circulating lipoproteins to exchange lipids and apoproteins. 
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Dietary Lipids and Atherosclerosis 
Numerous studies have shown a link between circulating lipoprotein levels and 
atherosclerosis. Specifically, lipoprotein imbalances are significant risk factors for 
atherosclerosis.  High levels of LDL cholesterol (referred to as “bad cholesterol”) and low 
levels of HDL cholesterol (referred to as “good cholesterol”) are clinical hallmarks of the 
disease as the levels of circulating lipoproteins correlate with the severity of coronary 
atherosclerosis (58-61).  HDL is important in reverse cholesterol transport because of its 
ability to transport lipids from peripheral cells to the liver for removal.  Thus, low 
circulating levels of HDL-cholesterol are associated with a higher risk for coronary heart 
disease (62-64). High levels of LDL-cholesterol are proatherogenic, as their presence in 
the lesion contributes to macrophage foam cell formation. However, the role of 
circulating TG-rich lipoproteins in atherogenesis is less defined.   
Importantly, studies showing a positive correlation between VLDL and 
atherosclerosis typically examine the effect of β-VLDL on atherogenesis. β-VLDL is an 
abnormal cholesterol-rich lipoprotein found in hypercholesterolemic animals and is very 
different from normolipidemic, TG-rich VLDL (65).  Some insight into the role of 
normolipidemic VLDL and CMs in atherogenesis can be gleaned from studies of human 
patients with LPL deficiency or apolipoprotein C-II (apoC-II) deficiency (66-68).  Patients 
with these conditions have elevated CMs and VLDL, but do not have an increased risk 
for atherogenesis.  In contrast, patients with such deficiencies appear to be protected 
from atherogenesis.  Thus, it is possible that VLDL and CMs can prevent or ameliorate 
atherosclerotic lesion formation, although the mechanism is unclear.  The studies 
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presented in this dissertation provide critical insight into potential influences of TG-rich 
lipoproteins on atherogenesis.  The current studies focus on the affects of TRPs on 
macrophage foam cells, one of the critical mediators of atherogenesis. 
 
Atherosclerotic Foam Cell Development 
 Macrophages are central to the initiation, progression, and development of 
atherosclerotic plaques. One of the earliest events in atherosclerosis is the development 
of macrophage foam cells. Most of the sterol in foam cells is derived from the endocytic 
uptake of modified lipoproteins and extracellular lipid complexes (34,69,70). The critical 
first step in the cell’s attempts to eliminate this sterol is delivery of the particles, via 
endocytic vesicles, to late endosomes/lysosomes where CEs are hydrolyzed. Under 
normal conditions, the FC generated from CE hydrolysis, is actively removed from 
lysosomes and used either for membrane synthesis or stored as cytoplasmic CE (71). 
Excess FC is toxic and must be cleared from the cell as an intact, hydrophobic molecule. 
In most cells this clearance is initiated by transport to the plasma membrane (PM) 
followed by efflux to acceptor particles in the extracellular milieu (72,73). Most of the 
cholesterol that is not effluxed out of the cell is reesterified to a fatty acid (FA) by acyl-
CoA acyltransferase (ACAT) to CE and stored in extralysosomal cytoplasmic inclusions 
(69,74). In addition to re-esterification, some cholesterol can move into alternative 
metabolic pools that can act to signal specific changes in the macrophage. Among these 
are activation of apoptosis pathways or processing to 27-OH cholesterol, a liver X 
receptor (LXR) agonist (73,75-78). The foam cell is a major regulator of plaque 
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development (46,79). Thus, the increased cholesterol accumulation observed in foam 
cells can impact macrophage function in multiple ways that can influence lesion 
development. For this reason, understanding what mediates foam cell intracellular 
cholesterol homeostasis is a major goal of atherosclerosis research.  
 
Macrophage Foam Cell Cholesterol Homeostasis 
 Macrophage cholesterol balance is influenced by cholesterol synthesis, 
lipoprotein uptake, CE storage, and cholesterol efflux.  Several intracellular pathways 
exist to control each step in cholesterol homeostasis. Importantly, when one 
homeostatic pathway is disrupted, the other attempt to compensate for the disruption, 
in order to maintain the balance of intracellular cholesterol levels.  Overburdening of 
the compensatory processes that maintain cellular cholesterol homeostasis results in 
the massive increases in cholesterol observed in macrophage foam cells.  
 
Cholesterol Synthesis 
 Macrophages are able to synthesize their own cholesterol in a highly regulated 
process that recognizes and responds to intracellular cholesterol levels. The 
endoplasmic reticulum (ER) is the critical site of cholesterol homeostasis, as it is the 
primary site for cholesterol synthesis and esterification.  The rate-limiting enzyme of the 
pathway is hydroxymethylglutaryl CoA reductase (HMG-CoAR), which generates 
mevalonate from the reduction of HMG-CoA. Importantly, HMG-CoAR activity is highly 
regulated through feedback inhibition by cholesterol in a mechanism involving sterol 
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regulatory element binding proteins (SREBP) and SREBP cleavage activating protein 
(SCAP).  SCAP has a sterol sensing domain that undergoes conformational changes in 
response to the cholesterol content of the ER membrane.  Under conditions of high 
cholesterol, SCAP confines SREBP to the ER, resulting in the inhibition of cholesterol 
biosynthesis (80). In contrast, when cholesterol levels are low, SCAP binds to and escorts 
SREPB to the Golgi where two proteases, site-1-protease (S1P) and site-2-protease 
(S2P), act sequentially to release the bHLH-Zip domain of the protein.  Following its 
cleavage, the bHLH-Zip domain translocates to the nucleus, where it acts as a 
transcription factor to activate the genes responsible for cholesterol synthesis (80). 
Although cholesterol synthesized by the cell can contribute to intracellular lipid 
homeostasis, it plays a very minor role in the lipid accumulation observed in foam cells 
because synthesis of cholesterol is tightly regulated and decreases when cholesterol 
accumulates (81). Thus, internalized cholesterol is the most significant contributor to 
the lipid burden in macrophage foam cells. 
 
Lipoprotein Cholesterol Uptake 
Several mechanisms have been identified for accumulation of exogenous 
cholesterol by macrophages.   LDL receptors (LDL-R) bind LDL particles in clathrin-coated 
pits for delivery to the endosomal-lysosomal system.  LDL is delivered to the lysosome 
where its lipids are hydrolyzed by acid lipases within the lysosome.  Depending on the 
levels of intracellular cholesterol, LDL-R can escape the lysosome and be recycled to the 
PM for continual uptake of LDL or, in cases of high cholesterol, the LDL-R can be 
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delivered to the lysosome for degradation (82). Similarly, LDL-R expression is sensitive to 
intracellular cholesterol levels, whereby negative feedback mechanisms can 
downregulate LDL-R expression in conditions of high intracellular cholesterol (83). 
Macrophages, however, possess alternate receptors for binding and internalizing 
lipoproteins (84-87). Within the atherosclerotic lesion, macrophages are exposed to a 
large quantity of modified LDL, including oxidized LDL (oxLDL) and aggregated LDL 
(aggLDL). The uptake of modified LDL occurs through the activity of macrophage 
scavenger receptors, including CD36 and scavenger-receptor A (SR-A) (figure 4).  In 
contrast to LDL-R, uptake of modified lipoproteins via these alternate receptors is 
unregulated, resulting in the continual uptake of lipoproteins, even under conditions of 
high intracellular cholesterol.  Accordingly, scavenger receptor-mediated uptake of 
lipoproteins is the most important lipid uptake pathway contributing to foam cell 
formation (88).   
 
Intracellular Cholesterol Storage 
 Excess cellular cholesterol is cytotoxic and, when intracellular cholesterol levels 
are high, the cell must find a way to safely store or process the excess sterol.  Cells do 
not have the capacity to degrade the complex cholesterol structure.  However, the cells 
have developed a number of mechanisms to store and efflux cholesterol.  Cholesterol is 
an important component of biological membranes and, when intracellular cholesterol 
levels are high, a significant amount of cholesterol can be incorporated into the plasma 
and other organelle membranes. However, in foam cells the capacity of membranes to  
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Figure 4: Macrophage cholesterol homeostasis is maintained by a number of highly 
regulated mechanisms.  Cholesterol homeostasis involves the balance of cholesterol 
biosynthesis, cholesterol uptake, intracellular sterol storage, and cholesterol efflux.  The 
key mediators of these pathways are identified in this diagram.  Modified cholesterol-
rich lipoproteins enter the cell through scavenger receptors such as CD36 and scavenger 
receptor-A (SR-A). Lipoproteins are delivered to the lysosome where they are degraded 
by lysosomal proteases and lipases.  Importantly, the cholesterol ester (CE) component 
is hydrolyzed by lysosomal acid lipase (LAL) to generate free cholesterol (FC) and a fatty 
acid (FA).  The FC can be transported to the plasma membrane for cholesterol efflux in a 
process mediated by the lipid transporters NPC1 and NPC2 and/or non-specific vesicular 
transport.  Alternatively, when cells are exposed to large quantities of cholesterol, 
excess FC is delievered to the endoplasmic reticulum where it can be esterified to a FA 
in a process mediated by the enzyme ACAT.  Following esterification, the CE can be 
stored in cytoplasmic droplets.  If the cell requires additional cholesterol, or if 
cholesterol efflux processes are activated, the cytoplasmic CE can be hydrolyzed by 
neutral CE hydrolase (NCEH). FC released from lysosomes or from cytoplasmic CE 
hydrolysis can be effluxed from the macrophage to cholesterol acceptors (including HDL 
and apoAI) through the activity of lipid transporters ABCA1, ABCG1, SR-BI and/or 
through passive diffusion. 
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incorporate cholesterol is exceeded and ACAT enzyme activity is activated (89-92).  
ACAT catalyzes the esterification of FC to FA generating CE, which can be stored safely in 
the cytoplasm as lipid droplets (69,93).  Concomitant with cholesterol esterification and 
incorporation of CE into cytoplasmic droplets, another enzyme, neutral cholesteryl ester 
hydrolase (NCEH), can hydrolyze CE back to FC (74,94). This hydrolysis can be stimulated 
further when FC levels drop, such as when cells are exposed to promoters of cholesterol 
efflux (figure 4)(95). The FC generated by NCEH supplies the cell with a source of 
cholesterol for use in cellular processes, including membrane synthesis. In the plasma 
membrane, FC can be effluxed to extracellular acceptors.   
 
Macrophage Cholesterol Efflux 
 In addition to storing excess cholesterol within the cell, in the presence of high 
intracellular cholesterol, macrophages are able to efflux excess FC. Macrophage 
cholesterol efflux can occur through four major pathways, including aqueous diffusion, 
SR-BI mediated efflux, ABC transporter mediated efflux, and apoE mediated efflux 
(figure 4).   
 
Aqueous diffusion is a passive process in which cholesterol spontaneously 
desorbs from the PM and enters the aqueous phase where the FC can collide with and 
be absorbed by HDL acceptor particles (72,96,97).  Importantly, aqueous diffusion is 
driven by the cholesterol concentration gradient, meaning that the direction and 
Passive Cholesterol Efflux Mechanisms 
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transport of cholesterol must occur from areas of high FC concentration to an acceptor 
with low FC concentration (72,97).  Thus, aqueous diffusion is an inefficient, passive 
cholesterol efflux mechanism, which occurs on the time scale of hours.    
 
Scavenger-receptor class BI (SR-BI) is responsible for the bidirectional, active 
transport of cholesterol across the PM. Similar to aqueous diffusion, the net movement 
of cholesterol via SR-BI is dependent on the cellular cholesterol concentration gradient 
(98-100).  If intracellular levels of cholesterol are low, SR-BI can bind to oxLDL and 
mediate its influx (72,101-103). In contrast, when intracellular cholesterol levels are high 
SR-BI can efflux FC to HDL (72,98-100,102,104). 
Active Cholesterol Efflux Mechanisms 
Cholesterol efflux can also occur through the function of ATP-binding cassette 
transporter AI (ABCA1) or ATP-binding cassette transporter G1 (ABCG1).  ABCA1 and 
ABCG1 are ATPases that hydrolyze ATP to generate energy for the unidirectional 
transport of lipids to extracellular acceptors.  ABCA1 promotes the efflux of FC and 
phospholipids (PLs) to lipid-poor amphipathic helical proteins such as apolipoprotein AI 
(apoAI) and apolipoprotein E (apoE). Absorption of PL and FC by apoAI is thought to 
result in the formation of nascent HDL particles (105,106).  ABCG1 promotes the efflux 
of FC to nascent HDL particles, such as those generated by ABCA1 mediated efflux (107).  
Thus, it is possible that ABCA1 and ABCG1 can act sequentially, and together they 
mediate the efflux of 60-70% of FC movement from the cell (108,109).   
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Apolipoprotein E is a multifunctional protein that is synthesized by many 
peripheral tissues including macrophages.  ApoE can act as a cholesterol acceptor that 
can mediate efflux even in the absence of additional cholesterol acceptors (110).  
Addition of exogenous apoE can stimulate cholesterol efflux (111,112). Similarly, 
endogenous expression and secretion of apoE is known to enhance cholesterol efflux 
(113,114). Although the exact mechanism by which endogenous apoE enhances efflux is 
unclear, we know that following secretion from the macrophage, apoE is bound by 
heparin sulfate proteoglycans (HSPGs) on the cell surface, which tethers the molecule 
close to the PM.  Thus, the retention of apoE in the proximity of the PM can facilitate 
the diffusion of cholesterol to lipid-poor apoE, which may involve the aforementioned 
cholesterol transporters ABCA1 and/or SR-BI (115,116). 
 
The efflux of cholesterol via all known mechanisms is significant in reverse 
cholesterol transport (RCT).  Reduced cholesterol efflux from macrophage foam cells is 
observed both in vivo and in vitro (117,118). Mobilization of macrophage cholesterol has 
previously been shown to reduce lesion area and enhance lesion stability (50).  
Therefore, defining mechanisms to enhance macrophage cholesterol efflux is critical for 
lesion regression. 
Cholesterol Efflux from Macrophage Foam Cells is Reduced 
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Lysosomal Lipoprotein Processing and Macrophage Foam Cell Cholesterol 
Homeostasis 
 
 A critical first step in the uptake of lipoproteins and their delivery to 
lysosomes/late endosomes for subsequent processing is receptor-mediated 
endocytosis. The lysosome is an organelle containing acid hydrolases, important 
digestive enzymes that degrade a variety of endocytosed material. VLDL, internalized 
through LRP, and modified LDL, internalized through scavenger receptors, are initially 
delivered to lysosomes for degradation and processing.  Lipoprotein lipids, including 
both TG and CE, are degraded by LAL in the lysosome.  LAL hydrolysis of lipoprotein 
lipids is significant because the clearance of sterol from the lysosomes requires 
hydrolysis of CE.  FC formed from hydrolysis can be transported out of the lysosome 
through a number of mechanisms (figure 4). While the transport process is ill-defined, it 
involves both vesicular and non-vesicular pathways and key proteins such as NPC1 and 
NPC2 (119-122). Importantly, once liberated from the lysosome, sterol is available for 
utilization as a substrate for cellular processes and signaling pathways, including 
cholesterol efflux pathways (figure 4). Therefore, lysosomal processing of endocytosed 
lipoproteins is the significant first step for the cell to utilize lipoprotein cholesterol. 
 
Deficiencient Lysosomal Lipoprotein Processing Contributes to Atherosclerosis 
 During early atherosclerotic lesion development, CE accumulates mainly in 
cytoplasmic droplets in macrophages (123).  Cytoplasmic CE is formed from the ACAT 
reesterification of FC released from the lysosome following lipoprotein lipid lipolysis.  
However, as lesions progress to more advanced stages, substantial accumulation of lipid 
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occurs in foam cell lysosomes (123-125) suggesting an interruption in lysosomal 
processing and excretion of cholesterol. Studies of foam cells in culture have also 
demonstrated lysosomal cholesterol accumulation (9-11,126-132). These studies show 
that the buildup of CE within lysosomes is not the result of defective or insufficient 
lipase enzyme; however, the actual mechanism remains unclear (126,133). Our work 
has shown that cholesterol accumulation in lysosomes can inhibit CE hydrolysis (9-
11,13). Since CE cannot be cleared, it is trapped in the lysosome. 
 Multiple studies indicate that lysosomal sequestration of cholesterol can have 
negative consequences in atherosclerosis (1-8). In addition to a direct effect of 
accumulating sterol on lysosome function, sterol in lysosomes is trapped and 
unavailable for participation in other cellular processes (13). Not only can this trapping 
prevent removal of cholesterol by efflux, but it can also restrict cholesterol movement 
into alternative metabolic pools that act to signal specific changes in the macrophage. 
Among these are activation of apoptosis pathways and processing of cholesterol to 
oxysterols, which are LXR agonists (73,75-78). LXR activation influences a number of 
lipid homeostatic pathways including cholesterol clearance. Sterol-induced signaling 
pathways also influence cell viability (73). Thus, the foam cell is a major regulator of 
plaque development and rupture (46,79). For this reason, understanding the influences 
on cholesterol metabolism in foam cells is a major goal of atherosclerosis research.  
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Foam Cell Lysosomes and pH 
 A number of modified CE-containing particles can induce lysosomal cholesterol 
accumulation in cultured macrophages (134), including oxLDL, aggLDL, and CE-rich 
phospholipid dispersions (CE-DISP). Previous studies indicate that, initially, the 
macrophage can metabolize these particles, but the FC generated from hydrolysis is not 
efficiently removed from lysosomes. As FC accumulates, CE hydrolysis is inhibited and 
CE accumulates in lysosomes. Our preliminary evidence indicates that the inhibition of 
hydrolysis is due, at least in part, to a failure of lysosomes to maintain an acidic pH, 
perhaps related to the FC accumulation. LAL, the enzyme responsible for lysosomal CE 
hydrolysis, functions in a very narrow pH range with very little activity above pH 4.5 
(135). The optimal pH is established by unique electrogenic pumps called v-ATPases 
which translocate protons into the lysosome. Lysosomal pH is also determined by the 
leakiness of the lysosomal membrane (136). A number of factors, including sterols, can 
affect membrane permeability. FC can stabilize membranes and decrease leakiness, 
while oxysterols can increase leakiness, thereby affecting pH (71,137). Increased FC 
content in membranes can also inhibit v-ATPase activity, which potentiates changes in 
pH (138). Thus, the FC content of lysosomal membranes is a potential mediator of 
lysosome function.  
 
Importance of Triglycerides in Diseases of Cholesterol Metabolism 
Atherosclerosis studies have generally focused on cholesterol, because it is the 
principal lipid accumulating within the atherosclerotic lesion (139). However, TRPs have 
28 
 
the potential to enter the arterial wall and be incorporated within atherosclerotic 
plaques (140-145). TG is transported in the bloodstream as a component of TRPs, 
including CMs and VLDL and their corresponding remnants. TRPs can be internalized by 
macrophages via interaction of apoE found on their surface with a number of receptors, 
including LDL-receptor related protein (LRP), the VLDL receptor, and/or HSPGs (146-
153). The presence of TRPs in the lesion, as well as the ability of macrophages to 
internalize and catabolize TRPs, suggests that TGs could influence foam cell lipid 
metabolism.  
The role of TG in atherosclerosis is widely debated and highly controversial.  
Some studies suggest that elevated circulating TG levels are associated with increased 
atherosclerotic risk, while others show a benefit of circulating TG levels on 
cardiovascular disease. Univariate analysis of case-controlled and prospective cohort 
studies shows a positive correlation between TG levels and coronary artery disease 
(CAD) risk (154-158).  Specifically, high circulating levels of certain TRPs, including small 
VLDLs and IDL, have been independently linked with the incidence, severity and 
progression of atherosclerosis (159,160).  Small VLDLs and IDL are hypothesized to 
contribute to lesion progression, plaque rupture, and clinical coronary events through 
indeterminate mechanisms (158).   
One potential mechanism through which elevated circulating levels of VLDL 
could contribute to atherosclerosis is through their capacity to increase arterial 
inflammation (161,162). Previous studies show that exposure of vascular endothelial 
cells to VLDL increases the expression of nuclear factor-kappa B (NF-κB), a critical 
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transcriptional regulator of inflammation (162,163).  This results in the upregulation of 
proinflammatory proteins such as vascular adhesion molecules and chemokines, which 
enhance the recruitment of monocytes to the lesion (162,163).  Additionally, VLDL can 
activate proinflammatory gene expression in lesional macrophages, including 
upregulation of tumor necrosis factor-α (TNF-α), interleukin-1β, ICAM-1, matrix 
metalloproteinase 3, MCP-1 and macrophage inflammatory protein-1α (MIP-1α) 
(161,164-166). Thus, previous studies establish a relationship between TRPs and 
atherogenesis and suggest that increased circulating TRPs could increase CAD risk. 
Despite evidence establishing a prospective relationship between elevated 
circulating TG and increased CAD risk, a number of studies suggest that TG levels do not 
significantly impact the development of CAD. Specifically, multivariate analyses of 
epidemiologic data considering other lipid risk factors, such as levels of circulating HDL 
and small, dense LDLs, do not show a significant relationship between TG levels and risk 
(154-158,167). The majority of studies that find a correlation between elevated serum 
TG levels and CAD risk show that the influence of TG is minor compared to the effect of 
HDL-cholesterol even when serum HDL is included as a covariate (157). Thus, the results 
of multivariate analyses suggest that TG may not be considered a significant risk factor 
for CAD (168,169). Additionaly, analysis of the relationship between circulating TG levels 
and CAD risk is very complex given that TGs are carried in all circulating lipoproteins and 
present a different risk profile in the postprandial versus fasting state (156,158).  
Consequently, the relationship between circulating TG levels and atherosclerosis 
remains ambiguous. 
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Implications of Triglyceride in Macrophage Cholesterol Metabolism 
 Primary cultures of human monocyte-derived macrophages, as well as ex vivo 
human foam cell macrophages, contain TGs (144,170-172). Further, TGs are more 
metabolically active than CE and represent a dynamic lipid pool (118). Thus, the size and 
metabolic activity of intracellular TG pools may be an important component of 
macrophage lipid metabolism. Therefore, defining the interaction between TG and 
intracellular cholesterol pools is critical for understanding the role of TRPs in 
atherogenesis. Unfortunately, this is an understudied area of atherosclerosis research.  
 We do know that macrophages metabolize TG from TRP to glycerol and FA 
through surface hydrolysis and/or internalization and lysosomal hydrolysis (173,174). It 
is not clear (and somewhat controversial) what the relative importance of each is in 
determining intracellular TG and FA levels, and the contribution of each may change 
with TRP composition (173,175-177). However, FAs produced by both pathways are 
transported to the cytoplasm and can be reformed into cytoplasmic TG and stored 
within the same cytoplasmic droplets that store CE.  
 Cellular TG can influence intracellular cholesterol homeostasis. Macrophage 
lysosomes hydrolyze CE when it is introduced as mixed CE and TG particles compared to 
CE without TG (128). Studies indicate that this is because TG can alter the physical state 
of CE keeping it more fluid (128). This physical state effect is not limited to lysosomal 
hydrolysis. Association of TG with CE in cytoplasmic CE droplets makes the CE more 
susceptible to hydrolysis by NCEH (178,179). Since hydrolysis of CE is the first step in 
their mobilization, TG may well enhance cellular cholesterol removal (179).  
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 FAs, hydrolytically released from TG, are also influential in cholesterol 
homeostasis. FAs are key signaling molecules, which greatly affect the expression of 
critical genes controlling cellular cholesterol mobilization. FAs can act at the level of 
nuclear receptors to affect the transcription of a number of genes important in 
cholesterol homeostasis. For example, the individual or cooperative upregulation of 
peroxisome-proliferator activated receptor (PPAR) and LXR expression by FA has been 
shown to regulate expression of a number of cholesterol homeostatic genes including 
the ATP-binding cassette gene family members A1 and G1 (180), which enhance 
cholesterol movement and efflux.  FA can also influence the synthesis and secretion of 
apoE from macrophages, providing another mechanism through which FAs influence 
cholesterol efflux (181). Therefore, TRPs and/or their hydrolytic byproducts have the 
ability to enhance reverse cholesterol transport from macrophage foam cells, 
potentially resulting in atherosclerotic lesion regression. 
 There is an apparent paradox between epidemiologic studies suggesting that 
hypertriglyceridemia (HTG) may increase atherosclerosis and the cellular studies 
indicating a role for TG in cholesterol clearance. However, the epidemiologic evidence is 
controversial and does not define whether HTG has a direct or indirect effect on 
coronary disease (173). Patients with high TG invariably have other major risk factors for 
cardiovascular disease, including obesity, diabetes, and/or high blood pressure.  
Additionally, HTG is associated with low HDL cholesterol.  Thus, TG cannot be 
conclusively identified as an independent risk factor for atherosclerosis. A better 
understanding of how HTG directly affects cells in the artery wall is required to resolve 
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this paradox. An important component of this effort is defining the role of TRP as a 
modulator of cholesterol metabolism and foam cell biology.  
 
Significance 
Atherosclerosis is characterized by progressive thickening of the artery wall due, 
in large part, to the presence of lipid-engorged macrophage foam cells. In late stage 
disease, foam cell cholesterol is located within large, swollen lysosomes. Importantly, 
lysosomal cholesterol is trapped and unavailable to pathways of cellular cholesterol 
efflux.  Additionally, the massive cholesterol accumulation within lysosomes renders 
them inactive by inhibiting the activity of the v-ATPase, which is responsible for 
maintaining an acidic pH. The majority of studies examining the relationship between 
lipids and atherosclerotic foam cell formation have focused almost exclusively on the 
influence of cholesterol-rich lipoproteins.  While cholesterol is clearly important in 
atherogenesis, there are a number of lipids present within the complex atherosclerotic 
milieu that can influence foam cell lipid homeostasis. Specifically, TRPs are abundant 
within the artery wall and have the potential to substantially influence atherosclerotic 
lesion development by modulating foam cell lipid metabolism.  A limited number of 
preliminary studies suggest that TG could potentially influence foam cell cholesterol 
homeostasis by manipulating lysosomal CE hydrolysis, intracellular trafficking of 
cholesterol, storage of cholesterol within CE droplets, and cholesterol efflux. The goal of 
this dissertation research was to define the mechanism(s) by which TG modulates 
lysosomal and cellular cholesterol clearance from macrophage foam cells. 
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CHAPTER III 
 
 
 
EFFECT OF TRIGLYCERIDE ON LYSOSOMAL CHOLESTEROL METABOLISM IN THE 
MACROPHAGE FOAM CELL 
 
 
Introduction 
Atherosclerosis is a complex, multi-factorial disease.  An early event in 
atherosclerosis is the development of macrophage foam cells. These are primarily 
formed through the uptake of modified lipoproteins by macrophages within the artery 
wall (69,182-184).  In late stage atherosclerotic lesions, a large amount of both FC and 
CE accumulates in foam cell lysosomes. The presence of extensive amounts of CE 
suggests an interruption in the normal lysosomal hydrolysis of lipid particle-derived CE 
while the accumulation of FC indicates an interruption in the normal removal of FC from 
lysosomes to other organelles, primarily the plasma membrane (123-125).  Many 
studies indicate that lysosomal sequestration of cholesterol can have consequences for 
atherosclerotic lesion development (1-8). In addition to a direct effect of accumulating 
sterol on lysosome function, trapping of sterol in lysosomes can prevent removal of 
cholesterol by efflux. In fact, the FC and CE in lysosomes remains trapped in lysosomes, 
even when further uptake of lipoproteins is halted and acceptor concentrations in the 
media are increased to levels that remove most of the non-lysosomal CE stores (13). 
Thus the sequestration of sterol within lysosomes prevents efflux and limits the 
availability of cholesterol to other intracellular processes (13).  With this in mind, factors 
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that influence the removal of lysosomally sequestered sterol could have profound 
effects on foam cell biology and atherosclerotic lesion development.  
Many studies have examined macrophage foam cell metabolism in the presence 
of various CE-containing particles (182-184).  However, TRPs, including VLDL, are also 
present within the atherosclerotic lesion and could have an impact on foam cell 
cholesterol metabolism (145-149).  Surprisingly, the influence of TRP on metabolism of 
CEs has not been extensively studied. Lesion macrophages, primary cultures of human 
monocyte-derived macrophages, and ex vivo human foam cell macrophages, contain TG 
(144,170-172).  Moreover, TGs are rapidly turned over within macrophages and 
represent a dynamic lipid pool with the potential to influence cellular CE metabolism. 
Thus, defining the interaction between TG and intracellular cholesterol pools is critical 
for a full understanding of atherogenesis.   
A key observation linking TRP to CE metabolism is that  macrophages hydrolyze 
CE more efficiently when it is introduced into lysosomes as a mixed CE and TG particle, 
compared to CE-containing particles alone (128).  Additionally, it has been shown that 
TG can alter the physical state of CE by keeping it more fluid and accessible (128).  This is 
consistent with studies of cytoplasmic CE droplet metabolism, which demonstrate 
increased activity of lipolytic enzymes in the presence of mixed CE and TG droplets 
compared to CE alone (178,179).  Furthermore, FAs generated by lysosomal or extra-
lysosomal hydrolysis of TG are known ligands for, and can upregulate, cholesterol 
homeostatic genes, including LXR and PPAR (180,185-192). Therefore, it is clear that 
increased levels of TG in cells have the potential to affect macrophage CE metabolism.   
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In the current study, we investigate the potential for TG to reestablish lysosomal 
CE hydrolysis and to enhance the mobilization of the resulting FC out of lysosomes.  
Since CE cannot be cleared from lysosomes, lysosomal CE hydrolysis is the mandatory 
first step in cellular metabolism of lipoprotein-derived cholesterol and cellular 
cholesterol utilization or efflux. In this chapter, we show that treatment of macrophages 
with TRP before, during, or after cholesterol accumulation reduced both lysosomal FC 
and CE stores and promoted the eventual efflux of sterol from the cells. The alterations 
in lysosomal CE metabolism occurred, at least in part, through the ability of TGs to 
maintain normal lysosomal activity. Thus, we conclude that modulation of lysosomal CE 
metabolism, through alterations of cellular TG levels, has profound influences on the 
ability of foam cells to clear cholesterol. TRP flux through the atherosclerotic lesion and 
our studies indicate that uptake of these particles by macrophage foam cells can 
influence the ability of foam cells to metabolize the extensive lysosomal CE stores found 
in late stage lesions.  
 
Materials and Methods 
Materials 
THP-1 human monocytes/macrophages were purchased from ATCC (Manassas, 
VA). Bovine serum albumin (BSA), ethylenediaminetetraacetic acid (EDTA), cholesteryl 
oleate, trioleate, and cholesteryl methyl ether (CME) were purchased from Sigma-
Aldrich (St. Louis, MO).  Phosphatidylcholine (PC) and phosphatidylserine (PS) were 
purchased from Avanti Polar Lipids (Alabaster, AL).  Fetal bovine serum (FBS) was 
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obtained from Atlanta Biologicals (Norcross, GA), and RPMI, L-glutamine, Eagle's 
vitamins, streptomycin, and penicillin were purchased from Mediatech (Herndon, VA). 
All tissue culture plasticware was purchased from Corning (Corning, NY). All other 
chemical reagents and chemical solvents were obtained from VWR (West Chester, PA).  
 
Lipoprotein isolation and aggregation 
Human LDL was isolated from plasma collected from fasted, 
normocholesterolemic human volunteers who had provided informed consent.  
Collection of blood followed procedures approved by the Human Subjects Institutional 
Review Board. LDL (1.006 g/ml < d < 1.063 g/ml) and VLDL (d < 1.006 g/ml) were isolated 
by sequential ultracentrifugation (13). LDL and VLDL were dialyzed against 0.9% NaCl 
containing EDTA (0.3 mmol/l) for 72 h, filter-sterilized through a Millipore filter (0.45 
µm), and stored under nitrogen at 4°C. Isolated LDL was aggregated by vortex (1 min) 
followed by sonication with a Branson sonifier (10 min, 50% duty cycle) on ice to break 
up large aggregates.  The resultant aggregates were passed through a 0.45 µm filter, to 
produce small ( 30–75 nm) aggregates that induce maximal uptake and lysosomal 
delivery. Aggregation of LDL and size were confirmed by negative staining with 2% 
phosphotungstic acid. Measurement of thiobarbituric acid-reactive substances (TBARS) 
and conjugated diene levels confirmed the absence of oxidation after the aggregation 
procedure (193,194).  
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Preparation of Lipid Dispersions 
CE-rich or TG-rich lipid dispersions (DISP) were prepared under sterile conditions, 
as described by Mahlberg et al. (128). Briefly, phosphatidylcholine (1 mg), and 
phosphatidylserine (0.1 mg) and either cholesteryl oleate (30 mg, anisotropic) or triolein 
(10.35 mg, isotropic) were combined in a sterile 50 ml Corex glass tube and dried under 
nitrogen. RPMI medium (17 ml) supplemented with HEPES (12.5 mM) was then added 
and the suspension was heated in an 80°C water bath for 20 min to melt the dried lipids. 
The solution was sonicated for 20 min using a Branson sonifier (50% duty cycle). TBARS 
levels showed no oxidation after sonication of DISP. Dispersion size was confirmed by 
negative staining electron microscopy (EM) with 2% phosphotungstic acid (figure 5).  
 
Cell culture of THP-1 macrophages 
THP-1 macrophages were plated onto 35 mm wells or coverslips at a density of 
1.5 x 106 cells and incubated for 3–4 days at 37°C in RPMI containing 10% FBS and 50 
ng/ml phorbol ester (TPA), to allow for differentiation into macrophages. Culture media 
for all incubations was supplemented with HEPES (20 mmol/l), Eagle's vitamins, L-
glutamine (200 mmol/l), streptomycin (100 µg/ml), penicillin (100 IU/ml), and ß-
mercaptoethanol (0.008 µl/ml). TPA was included in the incubation medium throughout 
the duration of the experiments. Macrophages were incubated with medium containing 
1% fatty acid-free BSA for 24 h before cholesterol loading to minimize excess TG in cells 
prior to lipid loading.  
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Figure 5:  Characterization of lipid dispersions reveals similar sized particles in 
cholesterol-enriched (CE DISP) or triglyceride-rich (TG DISP) lipid dispersions. A: Diagram 
of the lipid dispersions.  DISPs contain a phospholipid membrane monolayer, that is 
primarily composed of phosphatidylcholine (PC) and phosphatidylserine (PS) in a 10:1 
ratio.  TG-DISPs have a TG-enriched neutral lipid core, while CE-DISPs have a CE-
enriched neutral lipid core.  B-D: Lipid dispersions containing either CE (B) or TG (C) are 
uniform in size with CE-DISP ranging from 9 – 38 nm (average diameter of 17.8 nm) and 
TG DISP ranging from 9 – 36 nm (average diameter of 21.5 nm)(panel D). Values are the 
mean ± SEM for three experiments.  Within each panel, bars with the same letter (a) 
indicate that means were not statistically different. 
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Lipid loading and analysis 
To measure lipid loading, macrophages were incubated for 0–6 days at 37°C in 
culture medium containing 1% FBS with or without lipid particles, including aggLDL, 
VLDL, CE-rich DISP, or TG-rich DISP. In some experiments, only one type particle was 
employed, while in other experiments both CE-rich particles (aggLDL or CE-DISP) and TG-
rich particles (VLDL or TG-DISP) were used either simultaneously or sequentially.  In 
sequential treatment during pulse-chase experiments, the pulse media was removed 
after three days of treatment and cells were washed briefly with 1% FBS prior to 
addition of the chase media for a further three days. Concentrations and specifics of 
incubation order are described for each experiment.  The lipid loading medium was 
changed every 3–4 days to fresh medium containing the cholesterol or TG loading 
vehicle.  
Loading with aggLDL or VLDL was done using standard culture techniques. In 
contrast, experiments using DISP were conducted using an inverted culture technique 
that has been previously described (128).  This method maximizes contact of cells with 
dispersions and the subsequent internalization of the particles (128). For the inverted 
technique, cells were first plated on glass coverslips on the bottom of 35 mm dishes. 
After adherence and differentiation, the coverslips were inverted and placed on sterile 
rings. Loading medium was then added so that the coverslip was submerged and the 
floating DISP came into contact with the adherent cells.  
For quantification, cellular lipids were extracted from cells with 2 ml isopropanol 
containing 5–10 µg of CME as an internal standard. Lysosomal lipids were extracted 
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from isolated lysosomes using the method of Bligh and Dyer with 5 µg of CME as an 
internal standard (195).  The cholesterol content of the lipid extracts were quantified by 
gas-liquid chromatography according to the procedure of Ishikawa et al. (196) as 
modified by Klansek et al. (197). TG content was quantified using a GPO Trinder assay kit 
from Raichem, according to the manufacturer’s instructions.  Cellular proteins and 
proteins in isolated lysosomes were solublized in 1 N NaOH overnight, and protein 
content was measured using the method of Lowry et al. (198).  Cellular lipid values are 
reported as µg cholesterol or TG normalized to mg cell protein while isolated lysosomal 
lipid values are reported as µg cholesterol or TG normalized to mg lysosomal protein. 
Cell viability during loading was assessed by counts of cell number and by protein 
levels. Experiments were performed in triplicate to assess experimental variability. The 
mean value for the three measures was used as the value for that experiment for 
subsequent statistical analysis of multiple experiments.  
 
Microscopy 
After lipid loading, microscopy was used to examine the subcellular localization 
of the accumulated lipids as well as to analyze changes in lysosomal environment.  
LysoSensor Yellow/Blue DND-160 staining (Molecular Probes, Eugene, OR) was used to 
determine changes in lysosomal pH (10,199). This dye fluoresces yellow in an acidic 
environment but the fluorescence wavelength shifts towards blue as the environment 
becomes more alkaline. For staining, cells were washed two times in PBS, and the dye 
was added to cells at a concentration of 5 µM in medium containing 1% FBS. All images 
41 
 
were collected within 10 min after the placement of dye on the cells to avoid artifacts 
produced by the alkaline properties of the dye. As a positive control, macrophages in 
which active lysosomes were increased by incubation of macrophage with polystyrene 
beads rather than lipoproteins were stained with LysoSensor Yellow/Blue DND-160. 
Images were collected using a Zeiss Axioplan Imaging E fluorescence/brightfield 
microscope (Zeiss, Germany) equipped with a Photometrics Coolsnap HQ digital camera 
with a cooled CCD chip (Roper Scientific, Tucson, AZ).  Image analysis was conducted 
using MetaMorph imaging software (Universal Imaging, Downingtown, PA).  To quantify 
changes in the number of active lysosomes, a grid of points was superimposed over 
each image. This provided an unbiased selection of vesicles to evaluate.  As previously 
published, vesicles with a pH less than 4.8 were classified as active while those with a pH 
above 4.8 were considered inactive vesicles (10).  A pH of 4.8 was chosen because LAL 
should have no activity above a pH of 4.8 and this value is above the pKa of LysoSensor 
such that there is a significant blue shift in the fluorescence of the probe. The vesicles in 
at least 20 cells per condition from three separate experiments were counted.   
Negative stain EM was used to determine the ultrastructural characteristics of 
the isolated lysosomes and to analyze changes in average lysosome diameter with the 
various treatments. Lysosomal isolates were absorbed to Formvar-caoted grids for 30 
seconds and then negatively stained for 20 seconds with 2% phosphotungstic acid, pH 
7.0.  Digital images were collected using a FEI CM-12 electron microscope operated at 80 
keV accelerating voltage and equipped with an AMT cooled CCD camera.  To determine 
the average lysosome diameter, a grid of points was superimposed over the images to 
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select, in an unbiased fashion, the lysosomes for quantification. The diameter of each 
selected lysosome was computed as the distance between the two most distant points 
on the lysosome periphery. At least 100 diameters were computed for each condition.  
EM was also used to assess the distribution of lipid in foam cells between 
lysosomes and cytoplasmic droplets. Lysosomes and related organelles were identified 
by the presence of acid phosphatase using a modification of the Gomori lead 
precipitation method (200,201). Beta-glycerol phosphate was used as a substrate, and 
the reaction control was incubated in identical medium without the enzymatic 
substrate. After incubation, cells were postfixed in 1% osmium tetroxide, dehydrated, 
and embedded in epoxy resin. Before further staining, the sections were viewed to 
verify the enzymatic reaction and then counter-stained with uranyl acetate.  
 
Lysosomal isolation and modification 
THP-1 macrophages were treated with various lipid particles, as described 
above, and then isolated as described previously (10). Briefly, the cells were rinsed in 
cold STE buffer (0.25 M sucrose, 0.01 M Tris-HCl, 1 mM EDTA, and 0.1% ethanol) and 
scraped into 1 ml/dish of STE buffer containing protease inhibitors (Sigma). The cell 
suspension was placed in a cell disruption chamber (Kontes) and disrupted using three 
passes of 20 min each at 150 p.s.i. This method consistently resulted in disruption of > 
95% of cells but left lysosomes intact. The suspension was centrifuged at 1500 RPM to 
separate the post-nuclear supernatant (PNS) from the nuclear pellet.  The PNS density 
was raised to 1.15 g/ml through the addition of sucrose and then applied to a sucrose 
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density gradient ranging from 1.28 g/ml to 1.00 g/ml.  The gradient was centrifuged at 
19,400 RPM for 4 hours at 4 °C to separate lysosomal fractions based on their buoyant 
density. Morphological analysis of the fractions by negative stain electron microscopy 
(as described above) revealed the presence of a reasonably pure lysosomal population 
with no apparent structural features of other organelles, including Golgi, rough 
endoplasmic reticulum, and mitochondria.  The purity of the lysosomal populations was 
assessed further by western blotting for markers of cellular organelles that might share 
common morphology to lipid-engorged lysosomes, including early endosomes (EEA1) 
and lipid droplet associated proteins (perilipin A).  Fractions were negative for EEA1 and 
perilipin and were positive for the lysosomal marker (LAMP-1, figure 6).  Lysosomal 
recovery was verified using western blotting of both the lysosome isolate and the 
nuclear pellet for LAMP-1 in comparison with whole cell extracts. LAMP-1 was not 
detected in the nuclear pellet. The isolated lysosomes were resuspended in buffer 
containing 150 mM KCl to generate high K+ levels inside the lysosome, which provided a 
membrane potential during the stimulation of the v-ATPase with ATP. Aliquots were 
obtained for cholesterol, TG and protein analyses, as described above.  
 
Vacuolar-type ATPase Activity 
Measurement of lysosomal v-ATPase activity was carried out using a 
modification of a procedure described previously (10,138).  Briefly, isolated lysosomes 
were placed in a cuvette containing activation buffer and 6.7 µM acridine orange. After 
achieving a steady spectrophotometric baseline, v-ATPases were primed with MgCl2.  
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Figure 6:  Western blot analysis of lysosomal, endosomal and lipid droplet markers.  
Analysis of isolated lysosomes showed the absence of markers of early endosomes (EEA-
1) and cytoplasmic lipid droplets (perilipin A) and the presence of the lysosomal markers 
LAMP-1 and LAL. Cells were treated with 100 µg aggLDL protein/ml and/or 100 µg VLDL 
protein/ml for six days and lysosomes were isolated according to the method described 
in the Experimental Procedures.  Fifteen micrograms of protein was loaded in each lane. 
Whole control cell fraction was utilized as a positive control (+) for antibody staining. C = 
Control, V = VLDL-treated, A = aggLDL-treated, VA = VLDL + aggLDL coincubation. 
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After approximately 60 seconds to allow the baseline to be re-established, v-ATPases 
were activated by the addition of ATP (1.4 µM final concentration) and valinomycin (to 
promote the movement of K+ from inside to out for membrane potential generation). v-
ATPase-driven pumping of hydrogen ions into the lysosome lumen, as measured by the 
quenching of acridine orange fluorescence when excited at 495 nm and recorded at 530 
nm, was determined using an SLM Aminco 8100 dual-wavelength spectrophotometer. 
As a control, lysosomes were activated in the absence of the requisite membrane 
potential by including valinomycin in the medium. 
 
Statistics 
For most analyses, the experiments were repeated at least three separate times. 
For replicate experiments, a mean, standard deviation, and standard error of the mean 
were determined. The value used for each separate experiment was the mean value 
determined from triplicate measures. Two group comparisons used Student's t test. For 
multiple comparisons, following an analysis of variance, group comparisons were 
performed with the multiple comparison HSD method of Tukey (202). The criterion for 
significance was set at P < 0.05 for a type I error. 
 
Results 
TRPs could potentially influence the foam cell metabolism of cholesterol. This is 
particularly true of the CEs derived from the uptake of CE-rich particles. These CE-
containing particles must first be processed within lysosomes. We have previously 
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shown that that this CE hydrolysis is inhibited in heavily cholesterol-laden foam cells 
primarily due to the accumulation of FC within the lysosome lumen and lysosome 
membrane (9,10). The lysosomally sequestered FC and CE are trapped and cannot be 
removed from the lysosome even under conditions that promote the removal of non-
lysosomal cholesterol from membranes and intracellular droplets (13).  To determine if 
TRPs affect the lysosomal metabolism of CE, cellular lipid levels were measured in THP-1 
macrophages treated with VLDL and aggLDL at the same time.  As controls, 
macrophages were incubated with aggLDL or VLDL alone. Consistent with what we have 
shown previously, incubation of THP-1 human macrophages with 100 µg aggLDL 
protein/ml produced a dramatic accumulation of both FC and CE (figure 7A). As in 
previous studies (9), thin section EM of acid phosphatase stained samples showed that 
>75% of the lipid volume was within lipid-engorged lysosomes. In contrast, co-
incubation of THP-1 with both aggLDL and VLDL resulted in a significant (p<0.05) 
reduction in the accumulation of CE (figure 7A). This correlated with a significant 
increase in cellular TG (figure 7B). When cells were incubated with aggLDL alone, 
significant TG accumulation was not seen. Thus, the presence of TG, delivered to the cell 
as a component of VLDL, reduced cholesterol accumulation, specifically CE, from aggLDL 
in THP-1 macrophages.   
The simplest explanation for our results would be that TG-rich and CE-rich 
lipoproteins compete for uptake. In order to determine the extent to which our 
observations were the result of competition for uptake, THP-1 cells were treated with 
I125 labeled aggLDL (50 µg aggLDL protein/ml) in the presence or absence of increasing  
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Figure 7: Accumulation of lipids in THP-1 macrophages incubated with aggregated LDL 
(aggLDL) and/or VLDL.  THP-1 macrophages were treated for 6 days at 37°C in RPMI 
containing 1% FBS and TPA (50 ng/ml) alone or with 100 µg protein/ml of aggLDL and/or 
VLDL. The cells were harvested and the cellular lipid levels were determined as 
described in Materials and Methods.  A: Incubation of THP-1 with aggLDL produced a 
dramatic increase in total cellular cholesterol seen primarily as a significant increase 
(p<0.05) in CE (light gray portion of bar). Although the FC (dark gray portion of bar) 
increased nearly two-fold compared with control, this difference was not statistically 
significant.  Incubation with both aggLDL and VLDL reduced the cellular CE accumulation 
compared to that seen with aggLDL alone. B: Incubation of cells with VLDL produced a 
significant (p< 0.05) increase in cellular TG levels compared to control or aggLDL-treated 
cells both when used alone or in combination with aggLDL.  Values are the mean ± SEM 
for three experiments.  Within each panel, bars with the same letter indicate that means 
were not statistically different.  All other comparisons were significantly different 
(p<0.05). 
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concentrations of VLDL (0, 10 or 50 µg VLDL protein/ml) for 48 hours (figure 8).  Results 
show no difference in particle uptake over a range of VLDL concentrations, indicating 
that VLDL treatment does not reduce uptake of aggLDL.  This suggests that the two 
particles do not compete for uptake and indicates a TRP-specific mechanism by which 
lysosomal CE metabolism and cellular clearance is enhanced.  
Lipoproteins are complex aggregates of lipids and proteins, both of which can 
influence the uptake and cellular metabolism of internalized material.  In order to rule 
out an effect of lipoprotein-derived protein on the process, protein-free DISP of PL and 
CE (CE-DISP, 60 µg CE/ml) were substituted for aggLDL and dispersions of PL and TG (TG-
DISP, 50 µg TG/ml) replaced VLDL. TG-DISP significantly reduced (p<0.05) the CE-DISP-
induced accumulation of CE (figure 9A). As with lipoproteins, this correlated with a 
significant increase (p<0.05) in cellular TG. There was no significant difference in cellular 
TG levels between incubation with TG-DISP alone and co-incubation with TG-DISP and 
CE-DISP, indicating that uptake of CE-DISP and TG-DISP was not significantly affected by 
co-incubation (figure 9B).  Thus, it appears that TG is required for the reduction of 
cellular cholesterol and is the primary mediator of the effects on cellular sterol 
metabolism. An even more dramatic reduction in cellular cholesterol concentration was 
accomplished when cells were first loaded with cholesterol from CE-DISP (60 µg CE/ml) 
and then chased, after removing CE-DISP from the media, with media containing TG-
DISP (50 µg CE/ml). The loading with CE-DISP more than doubled the cellular cholesterol  
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Figure 8:  VLDL and aggLDL do not compete for uptake and degradation. THP-1 cells 
were treated with 125I labeled aggLDL (50 µg aggLDL protein/ml) in the absence or 
presence of VLDL (0, 10 or 50 µg VLDL protein/ml) for 48 hours.  Squares represent 
internalized (i.e. cell associated) 125I labeled aggLDL, circles represent 125I labeled aggLDL 
that has been processed by the cells and discarded to the media, and triangles represent 
non-degraded 125I labeled aggLDL found in the media.  Results show no difference in 
particle uptake along the VLDL concentration gradient, indicating that VLDL does not 
reduce uptake of aggLDL. 
 
 
 
 
 
 
 
 
 
 
 
50 
 
 
 
 
 
  
 
 
 
Figure 9: Accumulation of lipids in THP-1 macrophages incubated with TG-DISP and/or 
CE-DISP. THP-1 macrophages were treated for 48 hours at 37°C in RPMI containing 1% 
FBS and TPA (50 ng/ml) alone or with the specified concentrations of lipid dispersions. 
Cells were cultured utilizing the inverted cell culture technique as described in Materials 
and Methods.  A: Incubation of THP-1 with 50 µg TG/ml TG dispersions (TG-DISP) alone 
did not significantly (p<0.05) alter cellular FC (dark gray portion of bar) or CE (light gray 
portion of bar). In contrast, incubation of cells with 60 µg CE/ml CE dispersions (CE-DISP) 
significantly increased the CE stores in cells. Co-incubation of cells with both CE DISP and 
TG DISP produced a significant (p<0.05) decrease in CE accumulation.   B: Incubation of 
THP-1 with 50 µg TG/ml TG DISP either alone or in combination with 60 µg CE/ml CE 
DISP produced a significant (p<0.05) increase in cellular TG compared to control cells or 
cells treated with CE DISP alone. Values are the mean ± SEM for three experiments. 
Within each panel, bars with the same letter indicate that means were not statistically 
different. All other comparisons were significantly different (p<0.05). 
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content and all of the accumulation was as CE. The chase with TG-DISP produced a 60% 
reduction in cellular total sterol with all of the reduction occurring as loss of CE.   
To further confirm that competition for uptake of aggLDL by VLDL was not the 
explanation for reduced cellular cholesterol and to more completely define the 
contribution of intracellular TG concentration on cellular lipid levels, we performed 
pulse-chase experiments with a constant concentration of aggLDL (50 µg aggLDL 
protein/ml) and varying concentrations of VLDL (5, 20, and 50 µg VLDL protein/ml).  TG 
treatment reduced cholesterol content in aggLDL-treated THP-1 macrophages in a 
concentration dependent manner (figures 10A and 10B). Importantly, the TG-effect was 
observed when the cells were incubated with VLDL either following (figure 10A) or prior 
to (figure 10B) aggLDL incubation. Moreover, the effect on cellular cholesterol was 
roughly proportional to cellular TG accumulation (figures 10C and 10D).  Therefore, TG 
reduces cellular cholesterol levels in a manner that is dependent on the cellular 
concentration of TG.  Furthermore, TG can prevent subsequent cellular cholesterol 
accumulation and can mobilize preexisting stores of cellular CE, including the large 
volume of sterol that accumulates in cellular lysosomes (9). This is in stark contrast to 
direct stimulation of extralysosomal cholesterol mobilization which does not affect the 
cholesterol trapped within lysosomes (11,13).  
We recently demonstrated that lysosomal accumulation of CE occurring in 
macrophages incubated with CE-rich particles, including oxLDL, aggLDL and CE-DISP, in 
large part, is the result of inhibition of lysosomal CE hydrolysis in response to an initial 
accumulation of excess FC within the lysosome (9-11).  Lysosomal CE hydrolysis is a key, 
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Figure 10: Incubation of THP-1 macrophages with VLDL decreases cellular FC and CE in a 
TG-dose dependent manner. THP-1 macrophages were pulsed for 3 days at 37°C in RPMI 
containing 1% FBS and TPA (50 ng/ml) with 50 µg protein/ml of aggLDL or the specified 
concentrations of VLDL (ranging from 5-50 µg protein/ml) followed by a 3 day chase 
period with either 50 µg protein/ml of aggLDL or the specified concentrations of VLDL. 
A: In cells preloaded with sterol by incubation with 50 µg aggLDL protein/ml, a chase 
with TG significantly (p<0.05) reduced total cholesterol accumulation over a range of 
VLDL concentrations (5, 20, and 50 µg protein/ml) in a dose-dependent manner. B: 
Preincubation of cells with VLDL also produced a significant (p<0.05) and dose-
dependent reduction in total cellular cholesterol accumulation from subsequent 
incubation with 50 µg aggLDL protein/ml. C and D: Incubation of THP-1 with increasing 
concentrations of VLDL produced a stepwise increase in cellular TG levels.  Values are 
the mean ± SEM for three experiments. Within each panel, bars with the same letter 
indicate that means were not statistically different. All other comparisons were 
significantly different (p<0.05). 
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rate-limiting step in the cellular clearance of exogenously derived sterol. Thus, the TG-
induced enhancement of cellular CE metabolism and loss of sterol from the cell suggests 
that TG alters lysosomal CE hydrolysis.  To study this further, we isolated lysosomes 
from cholesterol normal cells and cells under our various treatment conditions. EM of 
negatively stained isolates from various cellular subfractions indicates that the 
lysosomal fraction contained primarily membrane-limited vesicles having the 
appearance of lysosomes. Furthermore, these fractions were positive for LAMP-1, a 
marker for lysosomes/late endosomes (9,10), and LAL, the acid CE hydrolase (figure 6).  
Additionally, these fractions were negative for markers of early endosomes (EEA-1) and 
cytoplasmic lipid droplets (perilipin A) (figure 6).  Although the lysosomal fractions from 
each treatment group contained membrane-limited vesicles, differences in lysosome 
size and morphology were observed in lysosomes isolated from TG-enriched 
macrophages compared to those treated with cholesterol-enriched particles. The 
presence of small LDL-sized particles within the lysosomes isolated from cells incubated 
with aggLDL (figure 11) is consistent with our previous observations that, under 
conditions of cholesterol enrichment, CE-rich particles continue to be delivered to the 
lysosomes but digestion of the particles is inhibited (10). In contrast to treatment with 
cholesterol-rich vehicles (figure 11B), cellular TG enrichment results in lysosomes which 
are much smaller and have relatively homogenous luminal contents, indicative of active 
lipid particle digestion (figure 11C). Additionally, coincubation of aggLDL and VLDL 
(figure 11D) results in lysosomes that are similar in size and morphology to control 
lysosomes (figure 11A). The quantitative differences in lysosomal diameter are shown in 
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Figure 11: Negative staining electron microscopy of isolated lysosomes. THP-1 
macrophages treated with TRPs for 6 days had reduced lysosome diameter compared to 
macrophages that were only cholesterol enriched. Panels A-D show negative stain EM of 
lysosomes isolated from control cells (A), aggLDL-treated cells (100 µg aggLDL 
protein/ml, B), VLDL-treated cells (100 µg VLDL protein/ml, C), or cells co-incubated with 
aggLDL and VLDL (100 µg aggLDL protein/ml and 100 µg VLDL protein/ml, D).  Panel E 
shows the average lysosomal diameter determined from 3 separate experiments. 
Lysosomes from control cells were generally small and had a homogenous appearing 
lumen (A and E). In contrast, lysosomes from aggLDL-treated cells had significantly 
larger (p<0.05) lysosomes which had a variety of appearances but often contained a 
heterogenous mixture of apparently undigested material (arrows in figure B) within 
their lumen (B and E). Lysosomes from VLDL-treated cells were small with homogenous 
lumina similar to those isolated from control cells (C and E). Significantly, when THP-1 
were incubated with VLDL in combination with aggLDL, their lysosomes remained small 
and failed to develop the large, heterogenous appearance of lysosomes isolated from 
cells incubated with aggLDL alone.  Within each panel, bars with the same letter indicate 
that means were not statistically different. All other comparisons were significantly 
different (P < .05). Magnification for panels A, C and D = 40000X; Magnification for panel 
B = 25000X; bar = 500 nm. 
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figure 11E. These results are consistent with our hypothesis that cellular TG enrichment 
enhances lysosomal activity and clearance of lipid from the lysosome.  
Changes in the size and morphology of isolated lysosomes suggest enhanced CE 
hydrolysis and subsequent clearance of lysosomal sterol upon TG enrichment. To 
confirm this, we examined the effect of TG specifically on lysosomal sterol content. 
Treatment of cells with TRPs alone or in combination with cholesterol-rich molecules 
induced an increase in lysosomal TG levels while treatment with cholesterol-rich 
molecules alone resulted in increased lysosomal total cholesterol (figure 12). However, 
coincubation of cells with both TRPs and cholesterol-rich molecules resulted in a 33% 
reduction in lysosomal cholesterol (figure 12). As with the analysis on a whole cell basis, 
the reduction was almost exclusively in CE. This suggests that the reduction in cellular 
cholesterol begins with TG-induced changes in lysosomal CE hydrolysis.  
 Conversion of CE to FC is a critical first step in the removal of cholesterol from 
lysosomes. The hydrolysis of CE is mediated by the enzyme LAL, an acid hydrolase that is 
only functional at an acidic pH (135). Thus, the observed changes in lysosomal sterol 
levels are likely the result of effects on LAL. We do not observe changes in the cellular or 
lysosomal expression of LAL under the various lipid loading conditions (figure 13). 
Therefore, it is likely that the effects of TG involve changes in the environment in which 
the enzyme must function. Previously, we have shown that accumulation of excess FC in 
foam cell lysosomes leads to an inhibition of CE hydrolysis as a result of failure of the 
lysosomes to maintain the correct acid pH. Thus, the most probable candidate for the 
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Figure 12: Accumulation of lipids in lysosomes isolated from THP-1 macrophages 
incubated with aggLDL and/or VLDL. THP-1 macrophages were treated for 6 days at 37°C 
in RPMI containing 1% FBS and TPA (50 ng/ml) alone or with 100 µg protein/ml of 
aggLDL and/or VLDL. The cells were harvested following 6 day lipid accumulation and 
then lysosomes were isolated. The lysosomal lipid levels were determined as described 
in Materials and Methods.  A: Incubation of cells with aggLDL produced a significant 
increase (p<0.05) in the total cellular cholesterol that was seen primarily as increase in 
CE. In contrast, incubation of cells with VLDL did not produce an increase in lysosomal 
sterol. Importantly, co-incubation of THP-1 with both VLDL and aggLDL significantly 
reduced the lysosomal CE content. B: Incubation of THP-1 with aggLDL and VLDL 
together significantly increased (p<0.05) the amount of TG accumulating within 
lysosomes. Values are the mean ± SEM for three experiments. 
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Figure 13: Western blot analysis of LAL and LAMP-1. Analysis of cells treated with 
aggLDL and VLDL (100 µg lipoprotein/ml each for 6 days) and lysosomes isolated from 
similarly treated cells showed no difference in the expression of LAL between TG and/or 
CE loaded cells. Fifteen micrograms of protein was loaded in each lane and incubation 
conditions were as described in Experimental Procedures. Cells loaded with inert beads 
acted as a control for lysosome stimulation. ß-Actin was used as a loading control for 
whole cell fractions while LAMP-1 was used as a control for lysosomal fractions. C = 
Control, V = VLDL-treated, A = aggLDL-treated, VA = VLDL + aggLDL coincubation. 
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 TG reversal of the inhibition of CE hydrolysis would be the reestablishment of the acid 
pH to the lysosome.  
We measured the pH of vesicles within cells under our various treatments using 
Lysosensor Yellow/Blue DND-160, a pH sensitive dye (10). LysoSensor Yellow/Blue DND-
160 fluoresces yellow in an active lysosomal environment and has a significant blue shift 
as pH approaches neutrality (199,203). We classified intracellular vesicles as active if the 
pH was < 4.8 and inactive if the pH was > 4.8. This pH is at the upper limit of the 
accepted normal lysosomal pH and is well above the narrow active pH range of human 
LAL, which displays peak activity at pH 3.8–4.0 and possesses little activity above pH 4.5 
(135). Consistent with our previous studies, the majority of vesicles in untreated 
macrophages exhibited an active pH (figures 14A and 14F). Additionally, the majority of 
vesicles in cholesterol-enriched macrophages were inactive (figures 14B and 14F). 
However, examination of the vesicle pH in TG-enriched macrophage foam cells revealed 
differences in pH upon treatment with CE-rich compared to TG-rich lipoproteins. In 
contrast to cholesterol-rich foam cells (figure 14B), macrophages enriched with TG via 
treatment with VLDL did not display an alteration in the number of active vesicles 
(figures 14C and 14F). In fact, the presence of TG prevented cholesterol-induced 
lysosome neutralization when TG enrichment occurred concurrent with aggLDL 
accumulation (figures 14D and 14F). Moreover, when cells were loaded with sterol via 
aggLDL, subsequent treatment with VLDL reestablished an active pH to the previously 
inhibited vesicles (figures 14E and 14F). To confirm that most of the vesicles we 
analyzed were lysosomes, in separate experiments we used LAMP-1 staining to 
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Figure 14: LysoSensor Yellow/Blue DND-160 staining of lipid loaded macrophages.  
Enrichment of THP-1 macrophages with TG maintains and/or restores active lysosome 
pH.  A: After 6 days in culture, untreated lysosomes maintained an active (pH < 4.8), as 
indicated by a yellow fluorescence pattern. B: After 6 days of incubation with 100 µg 
aggLDL protein/ml, most lysosomes displayed a predominantly blue fluorescence, 
indicating an increase in pH to levels above 4.8. At this pH CE hydrolysis is inhibited. C:  
Macrophages treated with 100 µg VLDL protein/ml maintained a large population of 
active lysosomes (pH < 4.8).  D: Similarly, when cells were simultaneously incubated 
with 100 µg aggLDL protein/ml and 100 µg VLDL protein/ml, the lysosomes maintained 
activity, as evidenced by predominantly yellow fluorescence. E: When macrophages 
were incubated with 100 µg VLDL protein/ml after the cells were first incubated with 
100 µg aggLDL protein/ml, the VLDL-treatment was able to restore the pH of the 
lysosomes back to normal levels F: Quantification of the percentage of active (pH < 4.8) 
vesicles following the various treatment conditions Magnification of panels A-E = 500x. 
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investigate changes in the number of LAMP-1 positive vesicles under our various 
treatment conditions. Greater than 75% of vesicles in THP-1 foam cells were LAMP-1 
positive and the number of LAMP-1 positive vesicles did not significantly change 
(p<0.05) with treatment. Thus, the shift in percentage of active lysosomes was not the 
result of changes in lysosome number but rather represents the ability of lysosomes to 
maintain an active pH. Control cells incubated with polystyrene beads did not show a 
change in pH indicating that time duration was not the cause of changes in pH 
measurement; this was consistent with previous observations (10). EM analysis of acid-
phosphatase stained cells also indicates that most of the lipid accumulation was in 
lysosomes and the number of lysosomes was not appreciably altered with our various 
treatments. 
We have previously shown that cholesterol-induced inhibition of lysosomal 
acidification occurs primarily through the inhibition of the vacuolar ATPase, an integral 
membrane protein responsible for pumping H+ ions into the lysosomal lumen (10).  Loss 
of v-ATPase function occurred concurrently with the accumulation of FC in the lysosome 
and, specifically, within the lysosomal membrane. Our LysoSensor yellow/blue data 
suggest that TRPs accentuate CE hydrolysis by restoring lysosome pH. We hypothesized 
that the reduction in pH was due to TG-induced restoration of lysosomal v-ATPase 
activity.  To confirm this, we examined the activity of the lysosomal v-ATPase in isolated 
lysosomes from cells treated with TG, cholesterol, or both. Quenching of acridine 
orange fluorescence was our measure of the v-ATPase proton pump activity (10,138). 
Consistent with our published results (10), treatment with aggLDL alone (50 µg 
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aggLDL/ml, 6 days) resulted in deficient v-ATPase activity (figure 15). However, 
lysosomes isolated from cells treated with both aggLDL and VLDL (50 µg lipoprotein/ml 
each, 6 days) exhibited a rapid quenching of the acridine orange, comparable to control 
lysosomes (figure 15), indicating that the v-ATPases remained active. This suggests that 
TRP can help lysosomes to maintain an active pH by overcoming cholesterol’s normal 
ability to suppress the v-ATPases proton pumping.   
 
Discussion 
Much of our understanding of atherosclerotic foam cells focuses on the study of 
CE metabolism and accumulation, and most tissue culture models limit themselves to 
the study of the metabolism of cholesterol-rich particles. However, extracellular areas of 
atherosclerotic lesions contain a complex milieu with multiple lipid species, each of 
which could have a distinct influence on foam cell biology. In the present study, the 
influence of TRPs on macrophage CE metabolism was examined. TG was introduced 
through incubation of cells with VLDL or artificial TG-rich dispersions. Treatment with 
TRPs led to a reduction in total cellular cholesterol but more importantly, in lysosomal 
CE, in macrophage foam cells. This suggests that TG (or a metabolite of TG) is the 
mediating agent inducing the removal of sequestered sterol from foam cell lysosomes.   
Our data and that from previous studies suggest that the size and metabolic 
activity of intracellular TG pools can be an important component of macrophage lipid 
metabolism. Thus, it is important to define the interaction between TG and intracellular 
cholesterol pools in order to fully understand the flux of lipids within foam cells present 
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Figure 15: Activation of v-ATPases in isolated lysosomes following TG and/or cholesterol 
enrichment. Untreated lysosomes exhibited activation of v-ATPase and the pumping of 
hydrogen ions into the lysosomal lumen when stimulated by the addition of ATP and 
valinomycin (time 0), as indicated by the decrease in the relative fluorescence intensity 
of acridine orange. Lysosomes from macrophages that had been treated with 100 µg 
aggLDL protein/ml exhibited a lack of v-ATPase activity as evidenced by no reduction in 
the relative fluorescence intensity. In contrast, lysosomes from cells treated with 100 µg 
VLDL protein/ml, either alone or in combination with 100 µg aggLDL protein/ml, 
exhibited rapid quenching of acridine orange fluorescence, indicating active v-ATPases.  
Data is a representative of example chosen from multiple separate experiments. 
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in atherosclerotic lesions. However, despite some provocative reports (179,204), the 
role of TRP in foam cell cholesterol metabolism has not been studied extensively. In this 
chapter, we have demonstrated that cellular TG greatly influences lysosomal cholesterol 
homeostasis and significantly impacts atherosclerotic macrophage foam cell CE 
accumulation. Previous research on the interaction of TG-rich and cholesterol-rich 
lipoproteins has indicated a complex interaction between lipids which can have multiple 
effects within the macrophage. These potential interactions include the possibility that 
TG or its metabolites can alter the physical properties of the mixed lipid particles to 
enhance metabolism, can affect the affinity and activity of the enzymes responsible for 
lipolysis, and can regulate cholesterol metabolic metabolism and trafficking 
(128,178,179). For instance, cellular TG can increase the rate and efficiency of CE 
hydrolysis in macrophage lysosomes when the CE resides in a mixed lipid pool 
containing TG with lysosomes (128). This results, at least in part, from the ability of TG 
to alter the physical state of CE, keeping it more fluid (128). This physical state effect is 
not limited to lysosomal hydrolysis, as association of TG with cytoplasmic CE droplets 
has previously been shown to make CE more susceptible to hydrolysis by NCEH in the 
cytoplasm (178,179). Since the mobilization of cytoplasmic and lysosomal CE stores is a 
key mechanism for cellular cholesterol clearance (179), the ability of TG to mobilize 
intracellular cholesterol is highly significant. 
In this chapter, we have shown that increases in cellular TG drastically reduce 
cellular and, specifically, lysosomal cholesterol levels by maintaining the activity of foam 
cell lysosomes. Thus, our results are in line with previous studies demonstrating that TG 
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plays a significant role in altering the metabolism of cholesterol in macrophage foam 
cells. However, our studies are the first to reveal a reduction in lysosomal cholesterol 
levels in response to increased cellular and lysosomal TG content. This is not an 
unimportant finding. In advanced atherosclerotic lesions, it is estimated that greater 
than 70% of the lipid in a macrophage foam cell is sequestered in lipid enriched 
lysosomes (125,205). Moreover, our previous studies indicate that the cholesterol 
within lysosomes is trapped and is extremely resistant to treatments that mobilize and 
efflux other intracellular cholesterol stores (5,13). We and others have shown that 
enhancement of efflux promoters, including increases in ABCA1 or the extracellular 
concentration of free apoproteins or HDL, does not reduce lysosomal cholesterol stores 
(13,206). Therefore, TG-containing particles appear to be unique in their ability to 
promote lysosomal cholesterol clearance.  
Our studies also suggest that the effect of TG on lysosomal CE metabolism and 
cholesterol clearance from the lysosome is more complex than just alterations in 
enzymatic hydrolysis as evidenced by the influence of TG on lysosomal v-ATPase activity. 
The lysosomal v-ATPases are critical lysosome integral membrane proteins responsible 
for pumping H+ into the lysosomal lumen in order to maintain the acidic pH necessary 
for the function of lysosomal lipolytic enzymes. It is not clear whether TG directly or 
indirectly affects the pumps. We have previously shown that the activity of v-ATPases is 
sensitive to the FC content of the lysosome membrane (10). This is consistent with 
similar studies which have shown that the macrophage ER calcium pump, sarcoplasmic-
endoplasmic reticulum calcium ATPase-2b, is also sensitive to changes in membrane 
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fluidity induced by cholesterol content (207). Therefore, it is possible that the TG-effect, 
at least in part, is mediated through lysosome membrane changes, which enhance 
proton pumping, lysosomal acidification, and lipolytic enzyme activity. This possibility is 
addressed in chapter IV.   
It is also possible that TG, either directly or through its metabolites, influences 
the removal of cholesterol from lysosomes and into cholesterol efflux pathways. In this 
regard, while the egression of cholesterol out of lysosomes is not a well defined process, 
it is known that it primarily involves the intercalation of FC into lysosomal membrane 
followed by its subsequent removal via formation of FC-enriched vesicles that traffic to 
and fuse with other cellular membranes (208). Thus, TG-mediated effects on lysosomal 
membrane properties have the potential to influence this aspect of lysosomal 
cholesterol clearance. It remains to be determined how lysosomal TG influences 
lysosomal cholesterol clearance and to what extent membrane alterations are required. 
Insights into this question are addressed in subsequent chapters. However, the current 
study does indicate that the presence of lysosomal TG enhances the metabolism and 
removal of cholesterol both from the lysosome and, ultimately, from the cell. Further 
study is required to define the precise mechanism or mechanisms which drive the 
enhanced clearance. Our studies to date have shown that TG can restore lysosome 
function in foam cells by reestablishing the ability of lysosomes to maintain an acid pH. 
This leads to increased CE hydrolysis, as the initial step, in enhanced sterol clearance 
both from lysosomes and from the cell.  
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In addition to the potential modulation of the activity of lipolytic enzymes, the 
metabolic byproducts of TG could affect lysosomal and cellular lipid metabolism. 
Macrophages have previously been shown to metabolize TG from TRPs to glycerol and 
FA through surface hydrolysis and by internalization of TRPs and lysosomal hydrolysis 
(173). Thus, TG and its metabolic products would be found in lysosomes. The TG pool is 
metabolized more efficiently than CE (209). This suggests other ways that TG 
metabolites might impact lysosomal function. For instance, FAs generated from 
hydrolysis of TG are known to be influential in cholesterol homeostasis. FAs are key 
signaling molecules that greatly affect the expression of critical genes controlling cellular 
cholesterol mobilization (180,185-192). FAs can act at the level of nuclear receptors to 
affect the transcription of a number of genes important in cholesterol homeostasis 
(180,185-192). In particular, the individual or cooperative upregulation of PPAR and LXR 
expression by FA has been shown to regulate the expression of a number of cholesterol 
homeostatic genes, including the ATP-binding cassette gene family members A1 and G1, 
which enhance cholesterol movement and efflux (180). Free FAs might also elicit an 
effect within the lysosome. Additionally, it is possible that the FAs generated from the 
lipolysis of TG within the lysosome may influence lysosomal membrane properties 
either by direct intercalation into the membrane or by influencing the acyl chains, which 
are present on the lysosomal membrane phospholipids. This modification in the FA 
composition of the lysosomal membrane might improve membrane fluidity and 
enhance the activity of lysosomal integral membrane proteins, including the lysosomal 
v-ATPase (210-213). Previously, we have shown that increased membrane cholesterol, 
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which decreases membrane fluidity, can inhibit lysosomal proton pumping (10). These 
data taken together suggest several explanations for how TG uptake into lysosomes 
might influence macrophage foam cell lysosomal CE metabolism. Additional 
experimentation will be required to define the mechanisms underlying TG-induced 
enhanced lysosomal CE hydrolysis and clearance. Initial studies examining these 
possibilities are presented in the following chapters. 
There is an apparent contradiction between published epidemiologic studies 
suggesting that HTG may increase atherosclerosis, and our current cellular studies, 
which indicate a role for TG in cholesterol clearance. A number of points are worth 
noting in this regard. First, the epidemiologic evidence is controversial and does not 
determine whether HTG has a direct or indirect effect on coronary disease (173). 
Specifically, HTG has not been established an independent risk factor for 
atherosclerosis. High TG levels are typically associated with low HDL-cholesterol 
(169,214) and, when HDL-cholesterol levels are considered, the significance of HTG in 
atherogenesis is reduced or nullified (215). Therefore, it is unclear if HTG contributes to 
lesion formation separate from its effects on other atherosclerotic risk factors. A better 
understanding of how HTG affects cells in the artery wall is required to resolve this 
aspect of the paradox. An important component of that effort is defining the role of TRP 
as a modulator of CE metabolism and foam cell biology.  Secondly, it remains to be 
determined if the increased lysosomal cholesterol clearance induced by TG has a 
positive or negative impact on macrophage foam cell biology and, ultimately, lesion 
development. Although in most settings removal of foam cell cholesterol is thought to 
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have a positive impact, the massive removal of cholesterol from previously engorged 
lysosomes may generate high levels of cellular FC that overwhelm the normal 
homeostatic mechanisms. Furthermore, it is known that high FC levels within certain 
cellular pools are harmful to macrophages (46). Thus, cellular health is regulated not 
only by the levels, but also the cellular location, of cholesterol. As such, FC is essential 
for proper cellular growth and membrane stability, but excess cellular free cholesterol in 
the wrong location is cytotoxic (73,216). The sequestration of cholesterol within the 
lysosomal compartment may be a protective measure to save the cell from the toxic 
effects of accumulated FC. Further studies are required to sort out the relative risks and 
benefits of unleashing lysosomally-trapped cholesterol. 
Lysosomal cholesterol is a major constituent of clinically important 
atherosclerotic macrophage foam cells. Most importantly, the lysosomally sequestered 
FC and CE has been shown to be highly resistant to removal, even under conditions that 
promote extralysosomal cholesterol efflux (13,134). In the current study we have shown 
for the first time that in the presence of TG, cholesterol that had previously been 
sequestered in foam cell lysosomes, is removed from both the lysosome and the cell. 
Thus, the TG-induced removal of sequestered lysosomal cholesterol allows this sterol 
pool to be available for cholesterol efflux. Therefore, our data suggest that TG-induced 
removal of cholesterol from foam cell lysosomes, if properly managed, may prove to 
have a positive benefit. This may be important in developing therapies for 
atherosclerotic lesion regression, as the removal of cholesterol from macrophage foam 
cells has previously been shown to reduce lesion area and enhance lesion stability (50). 
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CHAPTER IV 
 
MECHANISM OF THE EFFECTS OF TRIGLYCERIDE ON LYSOSOMAL METABOLISM:  
ANALYSIS OF LYSOSOMAL MEMBRANE FLUIDITY AND LYSOSOME MEMBRANE 
PHOSPHOLIPID FATTY ACID COMPOSITION 
 
 
 
Our studies have shown that TG enrichment mobilizes lysosomal cholesterol in 
foam cells and restores lysosome function (chapter III); however, the mechanism by 
which these effects occur remains unclear.  The studies described in this chapter show 
that TG can reverse the cholesterol-induced changes in lysosome membrane stiffness 
and restore the normal fluidity of the lysosomal membrane, shedding some light on how 
TG might operate in the lysosome. 
 
Introduction 
V-ATPase activity is the driving force behind lysosome acidification. ATPases are 
a class of enzymes that catalyze the hydrolysis of ATP to produce energy for subsequent 
chemical reactions. The majority of ATPases are transmembrane proteins that use the 
energy generated from ATP hydrolysis to move solutes across biological membranes 
against a concentration gradient (217). The complex structure of ATPases consists of 
cytoplasmic and transmembrane domains, each of which play distinct, yet important 
roles in protein function. The cytoplasmic domain is the site of ATP hydrolysis, while the 
transmembrane domain consists of a channel that transports solutes, ions and other 
materials using the energy from ATP hydrolysis (217).  The transmembrane domains of 
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the three major classes of ATPases, (v-, F- and A-ATPases) contain “rotary engines” that 
convert the energy generated from ATP hydrolysis into mechanical energy. This energy 
is required for the movement of protons into the luminal space (217,218).  Importantly, 
the activity of integral membrane proteins, including ATPases, is sensitive to the 
composition of their membrane environment (207,219,220). Increasing membrane 
cholesterol content abolishes the activity of many ATPase isoforms, and the mechanism 
is likely due to the ability of cholesterol to change the properties of biological 
membranes (207,221-224).  
Previous studies from our laboratory show that when cholesterol accumulates in 
the lysosome, the ability of the lysosome to decrease its pH is impaired. This occurs 
primarily because cholesterol inhibits the function of v-ATPase, the integral membrane 
protein responsible for pumping H+ ions into the lysosomal lumen.  Furthermore, this 
loss of v-ATPase function allows FC to accumulate within the lysosomal membrane (10). 
Excess membrane cholesterol likely inhibits v-ATPase function by exerting physical 
restrictions on the rotation of the transmembrane motors (207,221,222) by increasing 
the order and rigidity of the membrane. This assessment, along with the TRP-induced 
changes in the lipid content of the lysosomal membrane we reported in chapter III 
(figures 12 and 15), forms the foundation of our hypothesis: TG enrichment restores the 
activity of the v-ATPase by increasing the fluidity of the lysosomal membrane via TRP. 
A number of factors can influence the fluidity of cellular membranes, including 
membrane cholesterol levels and the FA composition of membrane PLs (219,225).  Thus, 
in addition to analyzing foam cell lysosomes for their fluidic properties, we also 
73 
 
investigated the effects of TG on the lysosomal membrane.  TRPs deliver TG to the cell 
where lipases on either the cell surface or in lysosomes can metabolize the TG from 
TRPs (177,226).  Cellular lipids rapidly reincorporate the FAs generated by either of 
these groups of lipases into cellular lipids, including CE, TG and PLs.  Thus, treatment 
with TRPs could alter the FA composition of membrane PLs by introducing this 
alternative pool of FAs (227).  
During membrane PL synthesis, cellular FAs function as substrates.  The acyl 
chains of cellular PL reflect the available pool of FAs. In turn, the acyl chains of PL can 
influence membrane properties. For instance, PLs containing shorter acyl side chains 
and/or acyl side chains with a higher degree of saturation reduce the melting point of 
cellular membranes and, as a result, reduce membrane fluidity (228,229).  We 
hypothesize that treating macrophages with TRPs alters the PL and FA composition of 
lysosomal membranes, influencing the fluidity of the lysosomal membrane. These FA-
induced changes could explain the alterations in lysosomal v-ATPase activity that occur 
following treatment with lipoproteins (chapter III, figure 15).   
 
Materials and Methods 
Membrane Order 
 We analyzed membrane order by electron paramagnetic resonance (EPR) 
spectroscopy, as described by Li et al. (207). Specifically, we used 5 µl of a 0.28 mM 16-
doxyl-phosphatidylcholine (16-doxyl PC) spin label probe (Avanti Polar Lipids, Alabaster, 
AL) in methanol, adding it to a 250 µl, 1mg/ml solution of isolated lysosomal membrane 
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fractions in sucrose buffer. In order to allow spin label incorporation into lysosomal 
membranes, we rotated the solution end-over-end at room temperature for 30 min. We 
then isolated the lysosomes by ultracentrifugation at 14,000 x g for 10 min at 4o C, and 
transferred the pelleted material to a quartz capillary tube for EPR measurements at 37o 
C. Using a Bruker Variable-Temperature Unit, (Billerica, MA), we obtained EPR spectra 
and performed calculations according to published methods (207). As described in the 
previous chapter, we correlated ESR measurements to measurements of lipid mass, 
including TG and cholesterol. We carried out the analyses in collaboration with Eric 
Hustedt and the Vanderbilt University Center for Structural Biology. 
 
FA composition of isolated lysosomes 
We extracted lipids using the method of Bligh and Dyer (195), separating 
individual lipid classes by thin layer chromatography using Silica Gel 60 A plates 
developed in petroleum ether, ethyl ether, acetic acid (80:20:1) and visualized by 
rhodamine 6G.   We scraped PLs, diglycerides, TGs and CEs from the plates and 
methylated them using BF3 /methanol as described by Morrison and Smith (230) and 
analyzed the methylated FAs were extracted and analyzed by gas chromatography using 
an HP 5890 gas chromatograph equipped with flame ionization detectors, an HP 3365 
Chemstation, and a capillary column (SP2380, 0.25 mm x 30 m, 0.25 µm film, Supelco, 
Bellefonte, PA).  Helium was the carrier gas we used, and we programmed the oven 
temperature to rise from 160 °C to 230 °C at 4 °C/min. By comparing the retention 
times to those of known standards we were able to identify FA methyl esters, and we 
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could quantify the amount of lipid in the sample by including lipid standards with odd 
chain FAs.  We used dipentadecanoyl phosphatidylcholine (C15:0), diheptadecanoin 
(C17:0), trieicosenoin (C20:1), and cholesteryl eicosenoate (C20:1) as standards.   
 
Results 
Although previous studies have proven EPR spectroscopy useful for the 
measurement of the order of membrane lipids in the endoplasmic reticulum (207), it 
was necessary to determine whether the technique could be effective for measuring 
lysosomal membranes. We treated THP-1 macrophages with varying combinations of CE 
or TG-rich vehicles (aggLDL and VLDL, respectively) to induce varying degrees of cellular 
and lysosomal cholesterol and TG accumulation. EPR analysis of isolated lysosomal 
membranes revealed characteristic two component spectra (figure 16), with 
“hyperfine” and “broad” components.  The broad spectral component appears in the 
analysis due to the tendency of the 16-doxyl PC molecules to cluster together, causing 
strong interactions between spin-labels. The broad component remains constant across 
all treatments, as sample membrane composition does not influence the interaction 
between spin labels. However, the hyperfine component of the spectra specifically 
represents the fluidity of sample membranes. Thus, we focused our analysis on the 
hyperfine spectral component to determine if there are specific changes in lysosomal 
membrane fluidity following lipid enrichment.  
The EPR curves of lysosomes treated with the various lipids are noticeably 
different from one another (figure 16). Treatment with TRPs (50 µg VLDL protein / ml) in  
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Figure 16: EPR spectra of isolated lysosomal membranes.  We treated THP-1 
macrophages with media alone (A), aggLDL (50 µg aggLDL protein /ml, B), or aggLDL and 
VLDL (50 µg lipoprotein / ml) for 6 days (C). Arrowheads indicate the portions of the 
spectra that are representative of membrane fluidity. Compared to a normal membrane 
fluidity profile (A), enrichment of lysosomes with cholesterol produced a spectra 
characteristic of a more rigid membrane, with the loss of integrity of spectral peaks. 
Coincubation of cholesterol and TG produces lysosomes with normal membrane fluidity. 
Quantification of EPR rotational parameter following EPR analysis of lysosomes treated 
with TG, cholesterol or both lipids shows similar membrane fluidity in TG-enriched 
versus normal lysosomes (D).  However, enrichment with cholesterol increases the 
rotational parameter, indicating a more rigid lysosomal membrane. 
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combination with cholesterol-enrichment (50 µg aggLDL protein / ml) produced spectral 
curves indicating normal lysosome fluidity, similar to lysosomes isolated from non-lipid-
loaded control cells (figures 16A and 16C).  This is in sharp contrast to treatment with 
aggLDL alone (50 µg aggLDL protein / ml), which results in a less defined curve, 
indicative of a rigid membrane structure (figure 16B).  Therefore, qualitative analysis of 
EPR spectra suggests a more rigid lysosomal membrane composition following 
enrichment with cholesterol, but the presence of TG can maintain normal membrane 
fluidity during cholesterol loading.  
 In order to assess quantitative changes in membrane fluidity, we analyzed our 
EPR spectra to determine the rotational parameter, which is a measurement of the 
rotational diffusion of the spin label electrons within the lysosomal membrane bilayer. 
Essentially, the more restricted the spin label is within the membrane, the higher the 
rotational parameter, indicating reduced movement of the spin label. Analysis of the 
EPR spectra revealed a 2.5-fold increase in the rotational parameter in cholesterol-
enriched cells, indicating a more rigid lysosomal membrane following sterol-enrichment 
(figure 16D).  In contrast, when we treated the lysosomes with cholesterol-rich and TG-
rich particles simultaneously, the rotational parameter was similar to non-lipid treated 
cells, indicating no difference in the membrane order (figure 16D).  This supports our 
hypothesis that, while membrane fluidity decreases with sterol accumulation, TRP-
treatment protects the lysosomal membrane from the cholesterol-induced alterations. 
A number of factors can influence membrane fluidity, including membrane 
cholesterol levels and the fatty acid composition of membrane PL side chains.  We have 
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previously shown a change in lysosomal cholesterol levels upon exposure to TG (shown 
in chapter III, figure 12).   However, it is possible that more than one mechanism could 
contribute to our observed changes in membrane fluidity. For instance, exposure to 
TRPs may alter the composition of cellular PLs.  Thus, we measured the FA composition 
of PL acyl side chains from isolated lysosomes to determine if there are changes 
following exposure to lipoproteins.  We treated cells for six days with aggLDL and/or 
VLDL (100 µg lipoprotein / ml) and isolated lysosomes as described previously (chapter 
III).  Results in table 2 show that each lipoprotein treatment altered the lysosomal FA 
profile. Both aggLDL and VLDL either alone or together induced a reduction in the 
percentage of PLs containing oleic acid (18:01) and docosahexaenoic acid (22:06).  
Similarly, lipid enrichment increased the concentration of linoleic acid (18:02) acyl side 
chains (table 2). In contrast, control and aggLDL treated lysosomes contained PLs with 
palmitoleic acid (16:01), eicosatrienoic acid (20:3w6) and docosapentaenoic acid (22:05) 
while those enriched in TG did not (table 2).   
The results in table 2 confirm that the various lipid treatments alter the acyl 
chain composition of membrane phospholipids.  Importantly, the composition of 
membrane PL acyl side chains can greatly influence membrane fluidity.  Membranes 
containing PLs with shorter-chain FAs or a lower degree of saturation are typically more 
fluid, due to a reduction in the interactions between side chains.  However, our analysis 
showed that lysosomes treated with aggLDL had the highest composition of 
polyunsaturated FAs, while lysosomes treated with VLDL had the highest composition of 
saturated FAs (table 3).  Additionally, we did not observe significant changes in side  
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Table 2: Analysis of PL acyl side chains from isolated lysosomes. THP-1 macrophages 
were treated for 6 days at 37°C in RPMI containing 1% FBS and TPA (50 ng/ml) alone or 
with 100 µg protein/ml of aggLDL and/or VLDL. The cells were harvested following the 6 
day lipid incubation and then lysosomes were isolated. The PL acyl side chain 
composition was determined as described in Materials and Methods.  Values are 
expressed as percentage of total FA found within the PL fraction. ND = not detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Con aggLDL VLDL V + A 
14:00 ND 0.59 ND ND 
16:00 20.68 15.98 21.77 21.61 
16:01 2.83 0.86 ND ND 
18:00 16.03 16.90 20.77 18.11 
18:01 25.06 14.56 18.71 18.34 
18:02 6.07 30.47 24.58 27.09 
20:3w6 3.63 2.23 ND ND 
20:04 10.25 11.95 8.84 10.03 
22:05 4.10 1.59 ND ND 
22:06 11.37 4.87 5.33 4.82 
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Table 3: Analysis of PL acyl side chains from isolated lysosomes, characterized by degree 
of saturation. THP-1 macrophages were treated for 6 days at 37°C in RPMI containing 1% 
FBS and TPA (50 ng/ml) alone or with 100 µg protein/ml of aggLDL and/or VLDL. The 
cells were harvested following the 6 day lipid incubation and then lysosomes were 
isolated. The PL acyl side chain composition was determined as described in Materials 
and Methods.  Values are expressed as percentage of total FA found within the PL 
fraction in each sample based on degree of side chain saturation. 
 
 
 
 
 
 
 
 
 
 
 
 Con aggLDL VLDL  V + A  
Saturated 36.71 33.47 42.54 39.72 
Monounsaturated 27.89 15.42 18.71 18.34 
Polyunsaturated 35.42 51.11 38.75 41.94 
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chain length among the various lipid treatments (table 4).  This is in sharp contrast to 
our membrane fluidity data that show a clear increase in membrane fluidity when TG is 
present and a clear decrease in membrane fluidity following treatment with cholesterol 
(figure 16).  Thus, it appears that while the PL-FA composition may exhibit an effect on 
foam cell membrane properties, the membrane fluidity is highly dependent on the FC 
content of the lysosomal membrane. 
 
Discussion 
Lipids are the major constituent of all biological membranes, and they undergo 
considerable metabolic turnover, as they are constantly degraded and resynthesized 
within the cell.  When macrophages encounter excessive amounts of dietary lipids, such 
as those found within the atherosclerotic lesion, the surplus lipids are catabolized 
completely and are readily incorporated into cellular lipids, including PLs. In foam cells, 
the substrates for lipid synthesis include TG, FAs and FC released from the hydrolysis of 
lipoprotein lipids.  Thus, exposure of cells to large amounts of lipoprotein-derived lipid 
can influence the composition of cellular lipids, including the PLs found within cellular 
membranes.  Our results show that under our treatment conditions, FA substrates 
dissociate and rapidly reincorporate into other cellular lipids in ways that could 
influence cholesterol metabolism.  
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Table 4: Analysis of PL acyl side chains from isolated lysosomes, characterized by chain 
length. THP-1 macrophages were treated for 6 days at 37°C in RPMI containing 1% FBS 
and TPA (50 ng/ml) alone or with 100 µg protein/ml of aggLDL and/or VLDL. The cells 
were harvested following the 6 day lipid incubaton and then lysosomes were isolated. 
The PL acyl side chain composition was determined as described in Materials and 
Methods. Values are expressed as percentage of total FA found within the PL fraction in 
each sample based on the length of the PL side chain. ND = not detected. 
 
 
 
 
 
 
 
 
 
 
 
  Con aggLDL VLDL V+A 
Long Chain 
Fatty Acids 
14 C ND 0.59 ND ND 16 C 23.51 16.84 21.77 21.61 18 C 47.16 61.93 64.06 63.54 20 C 13.88 14.18 8.84 10.03 22 C 15.47 6.46 5.33 4.82 
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Membrane Fluidity 
One way cholesterol metabolism can be affected by the fluctuations in the 
composition of FAs throughout the cell is through changes in membrane fluidity. Four 
major factors affect membrane fluidity (figure 17): 
• temperature 
• membrane PL acyl side chain length 
• degree of saturation of the membrane PL acyl side chain tails 
and 
• membrane cholesterol content  
Since atherosclerotic lesions exist at physiological temperatures, fluctuations in 
temperature do not play a role in our observed changes in membrane fluidity.  
However, in foam cells, the macrophages constantly interact with a variety of lipids 
including TG, cholesterol, CE, PL and, notably, FAs of varying degrees of saturation and 
side chain length, all of which can alter the other three key factors.   
Alterations in membrane PL and/or cholesterol content increase or decrease 
membrane fluidity by changing the complex interactions between lipids within the 
bilayer. To understand how these alterations occur, it is helpful to review how lipids 
interact in a membrane. Electrostatic and hydrogen bonds between head groups and 
van der Waals forces between the hydrocarbon tails hold together lipids in a membrane 
(231).  Van der Waals attractive forces stabilize the interaction between PL side chains, 
and the flexibility of the membrane decreases as the number of van der Waals 
interactions increases (231). For example, lipids with longer tails possess more surface  
84 
 
 
 
 
 
 
 
Figure 17: Diagram of PL and/or cholesterol interactions in cellular membranes that 
contribute to membrane fluidity. A: Chain length is an important determinant of 
membrane fluidity. Longer-chain FAs have stronger van der Waals forces (represented 
by dashed lines) than shorter-chain FAs due to increased surface area for interactions. B: 
Degree of FA side chain saturation influences membrane fluidity. The presence of 
double bonds in unsaturated FAs introduces kinks in the FA side chains, reducing the 
area for van der Waals interactions with neighboring PL side chains. C: Increased 
cholesterol content of the membrane decreases membrane fluidity by strengthening 
interactions between neighboring PLs. 
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area to interact with surrounding PLs. Thus, the PL side chains have stronger van der 
Waals interactions with surrounding lipids and exhibit more drag as they move through 
the membrane (figure 17)(231). However, the studies presented here show that the 
lysosomal membrane is composed of predominantly long-chain FAs (LCFAs)(table 4).  
Therefore, it does not appear that changes in PL side chain length explain the alterations 
in membrane fluidity we observe with lipid enrichment of lysosomes.  
The degree of saturation of the PL acyl side chains is another important 
contributor to membrane fluidity.  The extent of PL saturation affects membrane fluidity 
because unsaturated lipid tails, which contain one or more double bonds, are not able 
to pack as tightly as saturated lipid tails, which do not have double bonds (figure 17).  
The “kinks” present in unsaturated FA side chains reduce the attractive van der Waals 
forces between lipids in the membrane and, thus, increase membrane fluidity. We 
analyzed changes in saturation by comparing control lysosomes to cholesterol enriched 
lysosomes.  We found more PUFAs in cholesterol enriched lysosomes and more 
saturated FAs in TG enriched lysosomes (table 3).  Thus, if the degree of FA saturation 
was the key determinant of membrane fluidity, we would expect that TG-enriched 
lysosomes would be stiffer. This is the opposite of what we observe with EPR analysis. 
Thus, the changes we observe in PL acyl side chain composition are inconsistent with 
the hypothesis that degree of PL acyl chain saturation is a major determinant of 
lysosomal membrane fluidity in foam cells, at least in hypercholesterolemic cells.  
Altogether, the results of lysosomal PL side chain analysis and EPR analysis 
suggest that, in hypercholesterolemic cells, cholesterol may have a stronger influence 
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on lysosomal membrane fluidity than any effect of PL acyl chain saturation.  Cholesterol 
inserts itself into biological membranes and fits into gaps between membrane PL side 
chains, where the steroid ring interacts with and immobilizes PL fatty acids (231).  Thus, 
at physiological temperatures, the strong, additional van der Waals forces between 
cholesterol and membrane PLs would decrease membrane fluidity by stabilizing the 
interactions between membrane PLs. In chapter III, we showed significant changes in 
lysosomal cholesterol following lipid enrichment.  In particular, treatment with 
cholesterol-rich lipoproteins doubles the lysosomal cholesterol content, which 
correlates to the decrease in lysosome membrane fluidity observed in our EPR analyses 
(chapter III, figure 12 and figure 16). Importantly, we showed a 33% reduction in 
lysosomal cholesterol upon enrichment of foam cells with TG (chapter III, figure 12). 
This reduction in the cholesterol content of the lysosome and, specifically in the 
lysosomal membrane, would dramatically increase the fluidity of the lysosomal 
membrane. 
 
v-ATPase Activity 
In order to deal with stresses such as increases in membrane cholesterol, cells 
have developed a number of mechanisms to achieve constant membrane fluidity.  Such 
mechanisms consist of the regulation of membrane lipid composition.  For example, 
increased PL synthesis can counteract an increase in membrane cholesterol.  The 
changes in membrane PL content following lipoprotein treatment suggest that PL 
synthesis remains active following lipid enrichment, and could potentially serve as a 
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compensatory mechanism in response to the substantial influx of lipids.  However, given 
the abnormally high lipid levels present in a macrophage foam cell, it appears that it is 
difficult for the cell to effectively compensate for the substantial increases in membrane 
cholesterol.  As a result, the membrane lipids become restricted resulting in the 
inhibition of integral membrane protein function.  We hypothesized that in the 
macrophage foam cell, the inhibition of v-ATPase rendered the lysosome incapable of 
degrading endocytosed-lipoproteins, resulting in a large accumulation of lipids. 
Therefore, the ability of TG to restore lysosomal membrane fluidity and function could 
significantly improve the ability of foam cells to process and mobilize lipoproteins.  This 
would enhance the ability of atherosclerotic foam cells to efflux cholesterol, resulting in 
increased reverse cholesterol transport and potential lesion regression. Our data 
support this assessment, as treatment of cholesterol-enriched macrophage foam cells 
with TG restores lysosomal v-ATPase activity (chapter III, figure 15).  
A number of potential mechanisms could contribute to the increase in proton 
pumping including: 
• Increased v-ATPase protein expression 
• increased v-ATPase assembly at the lysosomal membrane 
• increased recruitment of v-ATPases to lysosomes  
and/or  
• changes in the v-ATPase membrane environment 
We have previously shown similar v-ATPase expression in cholesterol-enriched foam 
cells versus normal macrophages.   This suggests that expression of v-ATPases in 
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macrophages remains unchanged regardless of lipid loading (10), and indicates that the 
first mechanism is not relevant to our study.   Additionally, the cellular localization of v-
ATPases and the recruitment of subunits to lysosomes were unchanged in foam cells 
compared to normal lysosomes, suggesting that the v-ATPases are present and 
appropriately assembled in lipid engorged lysosomes. This seems to rule out the second 
and third mechanisms. Finally, v-ATPase activity is significantly impaired in foam cells 
(10), which points to changes in the v-ATPase membrane environment as the dominant 
mechanism in the regulation of lysosomal function. 
The activity of integral membrane proteins, including v-ATPase, is very sensitive 
to membrane fluidity.  Previous studies have shown that a number of ATPases with 
similarities to the lysosomal v-ATPase are greatly affected by the FC content of their 
membrane environment (220).  For example, FC enrichment of ER membranes inhibits 
the activity of the macrophage ER calcium pump, sarcoplasmic-endoplasmic reticulum 
calcium ATPase-2b (SERCA2b) (207).  Importantly, the inhibition of SERCA2b activity 
occurred in macrophage foam cells with similar lipid levels to the foam cells examined in 
the current study (207). Thus, our results are consistent with previous studies suggesting 
that changes in organelle membrane fluidity in macrophage foam cells greatly influence 
the activity of integral membrane proteins. 
Further Studies 
The quantitative measurements presented in this chapter involved analysis of 
the rotational parameter, which is one of many quantitative measurements of EPR 
spectra that we would require to reach a conclusion about membrane fluidity.  Two 
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other very important values are the order parameters (S0 and S2).  Order parameters are 
indicators of the degree rotation and amount of “wobble” of the spin label within the 
lipid bilayer. Measurement of order parameter in our lipid enriched lysosomes tended 
to be variable with no clear definition between various lipid treatments.  S0, which 
should be a positive value, is negative in many of our analyses, indicating random 
motion of the unpaired electron moiety within the bilayer.  Because of this random 
motion, we believe the difficulties obtaining reliable order parameter measurements 
are likely due to the location of the doxyl group on the spin label PL.  In the case of 16-
doxyl PC, the moiety with the unpaired electron sits deep within the membrane bilayer 
and its motion is less restricted.  Thus, its position in the bilayer results in less sensitivity 
to changes in membrane fluidity upon cholesterol and TG enrichment.  Future studies 
will be performed using alternative spin labels to probe different regions of the bilayer 
(figure 18).  However, the preliminary studies presented in this chapter show promising 
evidence suggesting that enrichment with cholesterol-rich lipoproteins increases 
lysosomal membrane stiffness while enrichment with TRPs reverses such changes,  
resulting in normal membrane fluidity. 
 
Conclusion 
Although there are some reservations, the results presented in this chapter 
appear to strongly suggest a relationship between lysosomal v-ATPase activity and 
lysosomal membrane fluidity. Increased membrane cholesterol leads to protein 
aggregation, increased lipid bilayer thickness, separation of lipid domains within the 
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Figure 18: Structure of the doxyl-PC spin label probes used for analyzing membrane 
fluidity.  Panel A depicts the structure of 16-doxyl-PC that was used in the ESR 
experiments described in this chapter.  Panels B and C indicate the structure of 
alternative PC-derived spin labels with different electron positioning on the PL fatty 
acids. Panel D depicts the location of the doxyl moiety within the lipid bilayer with red 
representing 16-doxyl-PC, orange representing 10-doxyl-PC and yellow representing 5-
doxyl-PC. 
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bilayer as well as restriction of the conformational freedom of proteins (220,232-234), 
and the FC-induced inhibition in SERCA2b activity in the ER of foam cells is likely due to 
the physical restriction of conformational changes required for functional ATPase 
activity (207).  Given the similarities in lipid content of the ER from the Li et al. study and 
the lipid content of the lysosomes shown here, it is likely that the activity of both 
ATPases are regulated through similar mechanisms. Thus, increases in lysosomal 
cholesterol content introduce physical limitations on the v-ATPases, preventing them 
from functioning (figure 19). The transmembrane domain of both SERCA2b and the 
lysosomal v-ATPase consists of a “rotary motor” which requires rotation of the 
transmembrane domain for the translocation of protons into the luminal space (218).  In 
the case of v-ATPase, the rotation of the transmembrane domain generates a proton 
motive force leading to the pumping of two hydrogen ions into the lysosomal lumen 
(217). Reduced membrane fluidity can restrict the rotational movement of the 
transmembrane domain (207,221,222).  Accordingly, the current studies show an 
apparent correlation between the fluidity of the lysosomal membrane, lysosomal 
cholesterol content and v-ATPase activity. 
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Figure 19: Summary of the effects of lipid enrichment on membrane fluidity and v-
ATPase activity. Compared to lysosomes from control cells (A), enrichment of the 
lysosomal membrane with cholesterol results in a decrease in membrane fluidity that 
restricts the rotation of the transmembrane domain of the lysosomal v-ATPase (B), 
rendering the v-ATPases inactive.  Treatment of foam cells with TG restores lysosomal 
membrane fluidity and v-ATPase activity. 
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CHAPTER V 
 
EFFECTS OF FATTY ACIDS ON MACROPHAGE CHOLESTEROL METABOLISM 
 
Enrichment of macrophage foam cells with TG mobilizes lysosomal and cellular 
cholesterol. Moreover, studies in chapter IV show significant changes in the FA 
composition of cellular lipids. Although we were unable to show a correlation between 
PL acyl chain composition and our observed alterations in lysosome function, it remains 
plausible that FAs generated from lysosomal and/or surface hydrolysis of TRPs could 
influence other aspects of foam cell cholesterol metabolism. Thus, this chapter 
examines the effects of FAs on overall cellular cholesterol content. 
 
Introduction 
Because of their high TG content, VLDL and CMs are the primary transporters of 
dietary fat and are highly concentrated stores of metabolic energy. The lipolysis of TG 
within a cell releases glycerol and FAs. The released FAs are degraded in a stepwise 
oxidative process (β-oxidation) that generates metabolic energy, the products of which 
are either used as substrates for cellular lipid synthesis or act as important activators of 
many cellular signaling pathways. Thus, TGs and hydrolytically released FAs represent a 
dynamic lipid pool that can greatly affect both the composition and turnover of cellular 
lipids. Given the rapid utilization of TG by peripheral cells, the flux of TG through 
macrophages may serve an important role in the mobilization of lysosomal and cellular 
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cholesterol rather than simply leading to the accumulation of intracellular TG. 
Therefore, it is important to consider the role of FAs generated from lipolysis of TRPs in 
the mobilization of intracellular cholesterol. 
FAs released following TG hydrolysis elicit important metabolic effects with the 
potential to influence atherogenesis, including activation of cholesterol and FA 
homeostatic signaling pathways. FAs modulate LDL receptor activity, ACAT activity, and 
the distribution of intracellular cholesterol (235-241). Additionally, FAs regulate the 
expression of genes involved in lipid and energy metabolism (table 5). FAs generated by 
lysosomal or extralysosomal hydrolysis of TG regulate the activity of several 
transcription factors important in cellular lipid homeostasis, including the nuclear 
receptors PPAR, LXR, and hepatocyte nuclear factor 4 alpha (HNF-4α) (180,185-192). By 
regulating the activity of these nuclear receptors, FAs control the expression of 
downstream cholesterol homeostatic genes, including cholesterol efflux transporters 
(ABCA1, ABCG1, SR-BI) and apoproteins (apoA1, apoE, apoCII, apoCIII) (table 5). 
FAs acquired from dietary sources also serve as important substrates for 
intracellular lipid synthesis. One of the most significant roles of FAs within cells is the 
synthesis of biological membranes. FAs are incorporated into membrane PLs by transfer 
to a glycerol backbone in a process mediated by the enzymes acyl-CoA:glycerol-3-
phosphate (GP) acyltransferase and acyl-CoA:l-acyl-GP acyltransferase (242,243). 
Similarly, FAs can be utilized for TG synthesis by diacylglycerol acyltransferase (DGAT) 
and CE synthesis via the activity of ACAT (244,245). Both TG and CE are present in 
cytoplasmic lipid droplets from advanced macrophage foam cells. 
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Table 5: Cholesterol homeostatic genes regulated by FAs. 
 
 
 
 
 
 
 
 
 
Nuclear 
Receptor 
Ligand(s) Target Gene(s) 
PPARs Saturated FAs LPL 
Unsaturated FAs CD36 
Omega-3 FAs Cyp4a, 4b 
Conjugated Linoleic Acids ABCA1 
LPL-treated VLDL ABCB4, ABCD2, ABCD3 
VLDL LXR (α + β) 
LXRα, β Unsaturated FAs (antagonizes) ABCA1 
PUFAs (minimally) ABCG1 
Oxysterols apoE 
 ABCG5 
 ABCG6 
 SREBP-1c 
 Cyp27A1 
 SR-B1 
HNF-4α, γ Saturated FAs (agonize) apo CII 
Monounsaturated FAs (antagonize) apo CIII 
PUFAs (antagonize) apo AI 
 apo AII 
 apoAiV 
 Cyp7a1 
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In the previous chapters, we showed an effect of TG on cellular cholesterol 
levels. However, it is unclear if TRPs reduce cellular cholesterol via direct effects of TG 
on cholesterol metabolism or through metabolic byproducts of TG. Therefore, the 
studies presented in this chapter sought to determine if treatment with FA could induce 
lysosomal and cellular cholesterol mobilization similar to TG. 
 
Materials and Methods 
Materials 
Tetrahydrolipstatin (orlistat), oleic acid (OA), linoleic acid (LA), and palmitic acid 
(PA) were purchased from Sigma-Aldrich (St. Louis, MO). 
 
Orlistat Treatment 
To inhibit the surface hydrolysis of VLDL TG, cells were treated with the 
lipoprotein lipase (LPL) inhibitor Orlistat. Three hours prior to lipid loading, cells were 
treated with 10 µM Orlistat in ethanol or vehicle control (100% ethanol). Following the 
three-hour preincubation, cells were treated with lipoproteins (VLDL and/or aggLDL, 100 
µg lipoprotein / ml media) for 24 hours. The concentration of Orlistat was maintained 
throughout lipid loading. 
 
Preparation of FA-BSA Conjugates 
FA-albumin conjugates were created using a modification of a procedure 
described previously (246). Briefly, OA, LA, and/or PA (12.0 mg each) were dissolved in 5 
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ml of 95% ethanol and were titrated with 1 N NaOH to a phenolphthalein end point (pH 
> 10). The ethanol solution was evaporated to dryness under nitrogen with warming at 
37 °C. Bovine serum albumin (FA poor, Sigma, 4.25 g) was dissolved in 25 ml of 0.9% 
NaCl for a final solution of 17% albumin. The pH was adjusted to 7.4 with a few drops of 
1 N NaOH. A volume of 17% albumin solution was added to the dry, warm FAs for a final 
molar ratio of 6:1 FA:albumin. OA and LA solutions were incubated at 40 °C for 2 hours 
in a water bath with gentle shaking. PA required stirring during the 40 °C incubation to 
prevent precipitation. 
 
Cell Culture and Lipid Loading of THP-1 Macrophages 
THP-1 macrophages were maintained as described in chapter II. To measure lipid 
loading, macrophages were incubated for 0 - 6 days at 37 °C in culture medium 
containing 1% FBS with or without lipid particles, including aggLDL as a cholesterol 
source and OA-, LA-, and/or PA-BSA conjugates as a source of FA. In some experiments, 
only one type of particle was employed, while in other experiments both CE-rich 
particles (aggLDL) and FAs (OA, LA, and/or PA) were used either simultaneously or 
sequentially. In sequential treatments for pulse-chase experiments, the pulse media was 
removed after three days of treatment and cells were washed briefly with 1% FBS prior 
to addition of the chase media for an additional three days. Concentrations and specifics 
of incubation order are described for each experiment. The lipid-loading medium was 
changed every 3 - 4 days with fresh medium containing the cholesterol or FA loading 
vehicle. Lipids and proteins were quantified as described in chapter III. 
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Results 
VLDL TG can be hydrolyzed at the cell surface by lipases and the FAs released by 
this hydrolysis are transported into the cell where they are resynthesized into cellular 
lipids, primarily TGs (174,226,247), resulting in intracellular TG accumulation. To 
determine if surface hydrolysis of TG influences cellular cholesterol levels, we used 
tetrahydrolipstatin (Orlistat, 10 µM) to inhibit LPL activity. In cells receiving Orlistat 
treatment, any cellular TG accumulation must occur through whole-particle uptake via 
the endosomal-lysosomal pathway. Treatment with TG-DISP in the presence of Orlistat 
had no effect on the accumulation of TG in the cell (figure 20B). Thus, TG-DISP enter the 
cell as whole particles via the endosomal-lysosomal system. Accordingly, Orlistat 
treatment did not inhibit the ability of TG-DISP to reduce cellular cholesterol 
accumulation in experiments where both TG-DISP and CE-DISP were included (figure 
20A). In contrast, when TG was delivered as VLDL, Orlistat did exhibit an effect on 
cholesterol accumulation from aggLDL. Consistent with previous studies (174,226), 
treatment of macrophages with VLDL in the presence of Orlistat reduced cellular TG 
accumulation by 60% (figure 20D). In cells coincubated with VLDL and aggLDL, the 
Orlistat-mediated reduction in cellular TG resulted in an increase in cellular cholesterol  
levels, similar to that observed with aggLDL treatment alone (figure 20A). Thus, the 
uptake of FAs, such as those generated by surface hydrolysis of VLDL TGs, could play a 
role in the TRP-mediated clearance of cholesterol. However, Orlistat produced a 
significant reduction in cellular TG. Thus, it is not clear whether the effect of FAs on  
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Figure 20: Accumulation of lipids in THP-1 macrophages incubated with TRPs and 
cholesterol-rich lipoproteins with and without LPL activity. Cells were either treated 
with TG-rich and/or CE-rich dispersions (A and B) or VLDL and/or aggLDL (C and D) and 
the cellular total cholesterol (A and C) or total TG (B and D) determined. Incubations 
were done in the absence or presence (Orl) of 10 µM tetrahydrolipstatin (Orlistat). 
When cells were lipid loaded using dispersions (DISP), inhibition of surface TG hydrolysis 
by LPL had no effect on either cellular cholesterol or TG accumulation during any of the 
treatment regimens (A and B). In contrast, Orlistat treatment reduced the ability of VLDL 
to promote clearance of cellular cholesterol from aggLDL, potentially by significantly 
reducing cellular TG levels (C and D). Values are the mean ± SEM for three experiments.   
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cellular cholesterol metabolism is direct or mediated through their reincorporation into 
cellular TG.  
To further define the effects of FAs on cholesterol metabolism, we treated 
macrophages with FA-albumin complexes in the presence or absence of cholesterol-
enrichment to determine if treatment with FAs could induce the clearance of 
cholesterol. Treatment of THP-1 macrophages for three days with OA-BSA complexes 
(250 µM OA +/- 50 µg/ml aggLDL) enhanced cholesterol clearance, as evidenced by a 
reduction in cellular cholesterol levels (figure 21A). OA was rapidly incorporated into TG 
within the cell and the cholesterol-reducing effect correlated with cellular TG levels 
(figure 21B). Importantly, OA is a monounsaturated FA that comprises approximately 
45% of our dietary fat (248). However, macrophages in a lesion are exposed to a range 
of FAs, including saturated, monounsaturated, and polyunsaturated species. Therefore, 
our initial analysis was limited in that it only examined the effects of one FA species on 
cellular cholesterol levels. To determine if the effects on cellular cholesterol were 
related to the degree of saturation of the FA, we performed studies using two additional 
FAs that are prevalent in circulating human plasma: LA, a polyunsaturated FA, and PA, a 
saturated FA. LA treatment (250 µM) produced similar cholesterol-lowering effects as 
OA (250 µM, figure 21B), and both induced similar increases in cellular TG (figure 21B).  
However, PA did not reduce the cholesterol content of the cells (figure 21A). Thus, 
unsaturated FAs may favorably influence cholesterol metabolism and efflux while 
saturated FAs do not. 
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Figure 21: Accumulation of lipids in THP-1 macrophages incubated with aggregated LDL 
(aggLDL) and/or oleic acid (OA), linoleic acid (LA) or palmitic acid (PA). THP-1 
macrophages were treated for 6 days at 37°C in RPMI containing 1% FBS and TPA (50 
ng/ml) alone or with 100 µg protein/ml of aggLDL and/or 250 µM FA. The cells were 
harvested and the cellular lipid levels were determined as described in Materials and 
Methods.  A: Incubation of THP-1 with aggLDL produced a dramatic increase in total 
cellular cholesterol observed primarily as a significant increase (p<0.05) in CE (light gray 
portion of bar). Incubation with both aggLDL and OA or LA reduced the cellular CE 
accumulation compared to that observed with aggLDL treatment alone. In contrast, 
coincubation with aggLDL and PA did not affect cellular cholesterol levels (p>0.05). Dark 
gray bars indicate FC levels, which were only minorly affected by FA enrichment. B: 
Concubation of cells with OA or LA with aggLDL produced a significant increase 
(p<0.001) in cellular TG levels compared to aggLDL-treated cells.  However, coinubation 
of PA and aggLDL did not significantly increase cellular TG levels compared to aggLDL-
treated cells (p>0.05). Values are the mean ± SEM for three experiments (n.s. = not 
significant). 
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The variance in the ability of FAs to mobilize cellular cholesterol appears to 
depend on the ability of each FA to be incorporated into cellular TG. PA is a poor 
substrate for TG synthesis while OA and LA are preferentially incorporated into cellular 
TG (249-255)(figure 21B). We hypothesized that the effects of FA on cellular cholesterol 
levels are dependent on their ability to be synthesized into cellular TG. To address this 
hypothesis, we treated cells with a mixture of three FAs (PA, OA, and LA). Coincubation 
of PA with unsaturated FAs results in the incorporation of PA into cellular TGs (250). 
Therefore, we anticipated that treatment with the mixture of three FAs would increase 
cellular TG and induce the mobilization of intracellular cholesterol. Consistent with our 
hypothesis, treatment with the mixture of FAs reduced cellular cholesterol to a similar 
extent as treatment with OA and LA individually (figure 22A). This correlated with an 
increase in cellular TG to similar levels observed with unsaturated FA treatment (figure 
22B). The FA-mediated reduction in cellular cholesterol levels appears to occur in 
correlation with cellular TG levels, indicating that de novo synthesis of TG is important 
for eliciting the cholesterol-reducing effects of FAs. 
Although PA did not have an effect on cellular cholesterol levels, it could still 
elicit an effect on intracellular cholesterol trafficking. We hypothesized that PA could 
mobilize lysosomal cholesterol, but following its release, the lysosomal FC liberated by 
PA would be subject to ACAT reesterifcation to PA in the cytoplasm. Thus, the liberated  
lysosomal FC would not leave the cell but would be stored as cytoplasmic CE. To 
determine if PA mobilizes lysosomal cholesterol, we treated cells with PA for six days 
and then chased with the cholesterol acceptor β-cyclodextrin (β-CD) for 24 hours. 
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Figure 22: Accumulation of lipids in THP-1 macrophages incubated with aggLDL and/or a 
mixture of OA, LA, and PA (3FA Mix). THP-1 macrophages were treated for 6 days at 
37°C in RPMI containing 1% FBS and TPA (50 ng/ml) alone or with 100 µg protein/ml of 
aggLDL and/or a mixture of 250 µM of each FA (750 µM total concentration). The cells 
were harvested and the cellular lipid levels were determined as described in Materials 
and Methods.  A: Incubation of THP-1 macrophages with the 3FA Mix significantly 
decreased total cholesterol and CE (light gray portion of bar) compared to treatment 
with aggLDL alone (p<0.001). B: Treatment with the 3FA Mix increased cellular TG levels 
compared to non-lipid loaded control cells and treatment with aggLDL alone. The results 
of the 3FA mixture treatment are similar to the results achieved with individual 
treatment of the unsaturated FAs (OA and LA, figure 21). Values are the mean ± SEM for 
three experiments.   
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Treatment with β-CD removes all cellular cholesterol with the exception of the sterol 
sequestered in lysosomes (13). Thus, if PA mobilizes cholesterol from the lysosome to 
the cytoplasmic lipid droplets, it will be in a pool accessible for removal from the cell via 
cholesterol efflux to β-CD. In contrast, if PA does not mobilize lysosomal cholesterol, it 
will not be available for efflux to β-CD and we would not observe an effect on cellular 
cholesterol levels following treatment with β-CD. Treatment of cells for six hours with 
aggLDL and PA, followed by a 24-hour β-CD chase, resulted in the clearance of a 
significant amount of cellular cholesterol (figure 23A). Thus, treatment with PA 
mobilizes lysosomal cholesterol, similar to unsaturated FAs. However, following its 
release, lysosomal sterol is reesterified to PA and stored as cytoplasmic CE droplets. The 
effect of FAs on lysosomal and cellular cholesterol metabolism appears to be complex 
and involves multiple steps, including generation of FAs and de novo TG synthesis. 
 
Discussion 
TRP-derived TG can enter macrophages through a number of pathways, 
including surface hydrolysis (LPL), receptor-mediated endocytosis (VLDL receptor and 
LRP), and/or whole particle phagocytosis (174,226,247)(figure 24). Since the mechanism 
of particle uptake could influence the ability of TG to alter macrophage cholesterol 
metabolism, we sought to define how the TRPs used in our studies were internalized by 
THP-1 macrophages. Consistent with previous studies, approximately 60% of 
intracellular TG in the macrophage was derived from surface hydrolysis of the VLDL TGs, 
as evidenced by a reduction in cellular TG upon treatment with the LPL-inhibitor,  
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Figure 23: Accumulation of lipids in THP-1 macrophages incubated with aggLDL and/or 
PA with (+CD) or without a 24 hour chase with β-CD. THP-1 macrophages were treated 
for 6 days at 37°C in RPMI containing 1% FBS and TPA (50 ng/ml) alone or with 100 µg 
protein/ml of aggLDL and/or 250 µM PA.  Following the 6 day incubation, cells were 
chased for 24 hours with 1% media alone or containing β-CD.  The cells were harvested 
and the cellular lipid levels were determined as described in Materials and Methods. A: 
Incubation of THP-1 macrophages with PA (250 µM each, 6 days) followed by a β-CD 
chase decreased free cholesterol (dark gray portion of bar) and cholesterol ester (light 
gray portion of bar) compared to treatment with aggLDL (p<0.001). This suggests that 
the cholesterol in PA treated cells is accessible to cholesterol efflux mechanisms. B: Cells 
incubated with PA alone or in combination with aggLDL followed by β-CD treatment 
exhibited higher TG levels compared to similar treatment groups that did not receive a 
β-CD chase.  Values are the mean ± SEM for three experiments.   
106 
 
 
 
107 
 
Figure 24: TRPs enter macrophages via a number of pathways. TG-DISPs (light green) are 
internalized predominantly as whole particles (without prior hydrolysis of their TG) and 
are delivered to the lysosome for hydrolysis (light green arrows). The uptake of TG DISP 
occurs primarily through whole particle phagocytosis. In comparison, TG from VLDL 
(dark green arrows) enters the cell via three distinct pathways: whole-particle receptor-
mediated endocytosis (LRP, VLDL-R), hydrolysis of TG via LPL and internalization of FA, 
and receptor-mediated endocytosis (LPL, VLDL-R) of remnant VLDL after initial 
processing via LPL.  Endocytosed particles are delivered to the lysosome where their TGs 
are degraded by lipolyic enzymes, including LAL. The FAs generated from this lipolysis 
are transported to the cytoplasm.  Additionally, FAs generated from surface hydrolysis 
of VLDL are transported into the cell. FAs generated by lysosomal and/or surface TG 
hydrolysis are utilized by the cell as substrates for lipid synthesis, including the TG. Each 
of these intracellular TG and FA lipid pools could influence cellular cholesterol 
metabolism. 
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Orlistat (174,226). In this case, FAs generated by the hydrolytic activity of TG are 
internalized and used for intracellular TG synthesis (figure 24). Comparing the effects of 
DISP delivery of CE and TG (which appears to work exclusively through whole particle 
uptake) compared to that from native lipoproteins (where surface TG hydrolysis can 
occur) indicates that surface hydrolysis of TG is not absolutely required for TG to exhibit 
an effect on foam cell cholesterol levels but TG degraded via surface hydrolysis may 
contribute to the overall lysosomal hydrolysis of CE and clearance of sterol from cells. 
How these two pathways may interact remains to be elucidated. 
FAs generated from the hydrolysis of TG and/or circulating in the plasma 
influence macrophage foam cell biology. FAs are quickly utilized for cellular lipid 
synthesis, including TG, PL, and/or CE. Additionally, FAs are found in circulation and are 
present in the artery wall in atherosclerotic lesions (256,257). FA could elicit similar 
effects on cellular cholesterol metabolism compared to treatment with TRPs, either 
associated with or distinct from the observed effects of TG. The studies presented in this 
chapter show that treatment with unsaturated FAs reduces cellular cholesterol, similar 
to the effect observed upon treatment with TRPs. The reduction in cholesterol occurs in 
tandem with an increase in cellular TG, suggesting that de novo TG synthesis is 
important for mobilizing cellular cholesterol. This is consistent with the TRP experiments 
presented in chapter III. 
The studies described in this chapter provide preliminary evidence that FAs 
induce a similar reduction in cellular cholesterol levels compared to TRPs. Future studies 
are required to expand on these initial observations and to confirm the differential 
109 
 
effects of saturated versus unsaturated FAs on cholesterol metabolism. For our initial 
studies, we selected FAs based on their importance in human nutrition, since they are 
abundant in milk products (PA), meat (PA), and oils (OA and LA)(258). PA, OA, and LA are 
the most abundant saturated, monounsaturated, and polyunsaturated FAs 
(respectively) in our diet (258,259). Furthermore, we treated cells with concentrations 
consistent with circulating plasma free FA levels in the postprandial state (260). 
Therefore, we believe our results are physiologically relevant and may represent 
interactions occurring in vivo. 
The differences between PA, OA, and LA in the mobilization of lysosomal and 
cellular cholesterol suggest the possibility of a multistep process for the removal of 
trapped cholesterol from the lysosome and the cell. Importantly, treatment with PA, a 
saturated FA that is a poor substrate for TG synthesis, did not reduce cellular cholesterol 
(figure 25C). However, treatment with β-CD was able to remove cholesterol from cells 
co-incubated with PA and aggLDL. Lysosomal cholesterol is not accessible for cholesterol 
efflux, even in the presence of efflux promoters, including β-CD (13). Specifically, 
entrapment of FC and CE in lipid-engorged lysosomes prevents sterol from being 
mobilized to the plasma membrane for efflux. Thus, PA treatment mobilizes lysosomal  
cholesterol to a cellular pool that is accessible to cholesterol efflux to β-CD (figure 25F). 
Therefore, our working hypothesis is that, in contrast to treatment with aggLDL alone, 
coincubation with PA mobilizes lysosomal cholesterol to the ER where it is reesterified 
to palmityl-CoA by ACAT. PA is able to mobilize cholesterol from the lysosome but 
liberated sterol is stored as cytoplasmic CE rather than being mobilized to the PM for 
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Figure 25: Summary of FA experiments. A: OA and LA are rapidly incorporated into 
cellular TG. The increase in cellular TG corresponds to a decrease in cellular cholesterol 
in cells coincubated with aggLDL and OA and/or LA-BSA conjugates. B: PA is poorly 
incorporated into cellular TG and as a result leads to cell death. Our studies support 
these previous studies and show poor incorporation of PA into cellular TG. C: Cells 
coincubated with PA and aggLDL do not exhibit the clearance of cellular cholesterol that 
occurs in cells treated with unsaturated FAs. Accordingly, coincubated cells have 
reduced cellular TG and increased cellular cholesterol, suggesting that in cholesterol 
enriched cells, PA is incorporated into cellular cholesteryl ester. D: Consistent with 
previous studies, coincubation of cells with OA and LA appears to shuttle more PA into 
TG synthetic pathways. E: When cells are coincubated with a mixture of PA, OA, and LA 
in combination with aggLDL, we observe an increase in cellular TG that results from the 
ability of unsaturated FAs to shuttle PA into TG synthetic pathways. Importantly, the 
increase in cellular TG correlates with a decrease in cellular cholesterol. This emphasizes 
the importance of intracellular TG synthesis in our effects on cellular cholesterol 
clearance. F: Treatment of cells coincubated with PA and aggLDL for six days with β-
cyclodextrin for 24 hours mobilizes intracellular cholesterol. Lysosomal cholesterol is not 
accessible to cholesterol efflux, even in the presence of efflux promoters, including β-
cyclodextrin. Thus, PA mobilizes lysosomal cholesterol to an intracellular pool that is 
accessible to cholesterol efflux (i.e. cytoplasmic CE). 
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 efflux. Lysosomal cholesterol is effluxed in two steps: the initial mobilization of 
cholesterol from the lysosome and the efflux of liberated cholesterol from the cell. A 
potential model for multistep cholesterol mobilization is described in figure 26. FAs 
generated by surface and/or lysosomal hydrolysis have the potential to mobilize 
lysosomal and cellular cholesterol. Importantly, the generation of FAs, including both 
saturated and unsaturated species, mobilizes lysosomal cholesterol through a 
mechanism that remains to be determined (figures 25A, 25D, 25E). However, the 
mobilization of liberated cholesterol from the cell is dependent upon the ability of FAs 
to be incorporated into cellular TG. Since unsaturated FAs are rapidly incorporated into 
cellular TG they are unavailable for reesterification to liberated cholesterol (figure 26A). 
Saturated FAs, which are poor substrates for TG synthesis, are preferentially reesterified 
to the liberated cholesterol and thus sequester the sterol in cytoplasmic CE droplets 
(figure 26B). 
The studies presented in this chapter emphasize that intracellular TG may 
provide positive and in some cases protective benefits in many cell types, including 
macrophage foam cells. It is unclear why certain saturated FAs, including PA, are poor 
substrates for TG synthesis. The differential partitioning of FAs into cellular lipids occurs 
as the result of the preference of some enzymes in the lipid synthetic pathways for 
unsaturated versus saturated FA substrates (261,262). Importantly, the inability of cell 
to incorporate PA into cellular TG pools is cytotoxic (249-255). PA induces apoptosis 
through a number of mechanisms, including ceramide synthesis, direct effects on 
mitochondrial permeabilization, ROS generation, and activation of ER stress 
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Figure 26: Model for the multistep removal of cholesterol induced by FA incubation. OA 
and LA (purple), which are rapidly incorporated into cellular TG, induce the removal of 
cholesterol from the lysosome and shuttle mobilized sterol to the plasma membrane for 
cholesterol efflux. Similarly, PA (orange), which is a poor substrate for TG synthesis, 
mobilizes lysosomal cholesterol. However, in the presence of increased FC in the ER, PA 
is reesterified to FC by ACAT, preventing its removal from the cell. 
OA and/or LA PA 
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(252,253,263,264). However, intracellular TG accumulation is protective against FA-
induced lipotoxicity. Specifically, cosupplementation of unsaturated FAs rescues the 
lipotoxic effects of PA by shuttling PA into TG synthetic pathways 
(249,250,255,263,265,266). Our data combined with the results of these previous 
studies suggest that intracellular TG synthesis can have a number of positive effects on 
macrophage foam cells, including reducing the cytotoxic effects of saturated FAs and 
mobilizing intracellular cholesterol into reverse cholesterol transport pathways. 
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CHAPTER VI 
 
 
 
PILOT STUDIES EXAMINING THE EXTRALYSOSOMAL EFFECTS OF TRIGLYCERIDE IN 
MACROPHAGE FOAM CELLS 
 
 
 
Our studies have shown that enrichment of macrophage foam cells with TG 
mobilizes lysosomal cholesterol and reduces the cellular cholesterol content.  This 
indicates that, in addition to lysosomal CE hydrolysis and free sterol clearance, the 
extralysosomal trafficking and efflux of sterol out of the cell may also be enhanced. 
However, the pathways by which FC is released from the lysosome and ultimately 
removed from the cell are unknown. We have examined the extralysosomal effects of 
released sterol, and the mechanism by which liberated lysosomal sterol exits the cell. 
 
Introduction 
We have previously shown that cholesterol is sequestered in the lysosome upon 
treatment with cholesterol-rich lipoproteins (9-13,267).  The current studies have shown 
that TG has the ability to mobilize significant quantities of sequestered cholesterol from 
the lysosome and, ultimately, from the cell.  The mobilization of such large amounts of 
FC could have drastic effects on cellular homeostasis, some of which are diagrammed in 
figure 27.  For example, FC is known to be cytotoxic and a potent activator of apoptotic 
pathways (44,46,73,268), and FC released from the lysosome must be processed into a 
non-toxic metabolite in order to prevent cytotoxic effects.  Thus, it is possible that once  
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Figure 27: Diagram of the extralysosomal effects of FC.  Following release from the 
lysosome, FC can be trafficked to the ER and/or the plasma membrane. Mobilization of 
FC to the ER increases the ER cholesterol content and initiates mechanisms of FC 
processing and/or mobilization.  FC can be processed by ACAT to form cytoplasmic CE 
droplets.  If not properly managed, increase in ER cholesterol results in the activation of 
ER stress and, ultimately, cell death via apoptosis. 
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released from the lysosome, FC is trafficked to the ER, where it is reesterified by ACAT, 
moved to mitochondria where it can be converted to oxysterol, or transported to the 
PM for efflux.  Additionally, if the flux of FC from the lysosome to the ER is too great, 
and if the FC is not mobilized or metabolized, the resulting increase in ER cholesterol 
could activate ER stress and, consequently, cell death via apoptosis.   
The studies presented in chapter III show a clear reduction in cellular cholesterol 
levels following treatment with TRPs (chapter III, figure 7 and figure 9) indicating 
enhanced efflux of sterol.  While the mobilization of lysosomal cholesterol is an 
important first step, it is not sufficient to induce cellular cholesterol efflux. Importantly, 
the TG-induced mobilization of foam cell cholesterol occurs in the absence of 
extracellular cholesterol acceptors, which would enhance the movement of cholesterol 
from the cell. This suggests that TG enrichment could activate and/or upregulate 
promoters of cellular cholesterol efflux including SR-BI, ABCA1, ABCG1, and/or apoE.  
In sum, the studies presented in this chapter have sought to define the 
extralysosomal effects of lysosomal sterol mobilized following TG enrichment. We 
systematically examined the potential downstream effects of liberated lysosomal FC 
including alterations in cholesterol homeostatsis (ACAT, ABCA1, ABCG1, SR-BI, apoE) 
and/or activation of ER stress (CHOP, phospho-eIF2a).   
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Materials and Methods 
Cell Culture 
 Cells were cultured as described in chapter III.  In some incubations, the ACAT 
inhibitor compound CP113,818 (1.5 µg/ml medium) was included in the culture medium 
to prevent reesterification of cholesterol in the cytoplasm. Comparison of FC and CE in 
cells with and without ACAT inhibition provided a means of determining whether CE in 
uninhibited cells was derived from ACAT or, rather, was unhydrolyzed lysosomal CE.  
Additionally, use of ACAT inhibitors allowed us to determine if lysosomally liberated 
cholesterol was trafficked to the ER for reesterification.  Treatment with acetylated LDL 
(acLDL) with or without ACAT inhibitors was used as a positive control, as cholesterol 
derived from acLDL is known to be rapidly transported into cytoplasmic lipid pools that 
are accessible to ACAT activity. 
 
Western Blotting  
Following incubation with aggLDL and/or VLDL (100 µg lipoprotein/ml), cells 
were washed three times in ice-cold PBS and solubilized in ice-cold buffer containing 
150 mM NaCl, 100 mM NaF, 50 mM tris-HCl (pH 8.0), 35 mM sodium deoxycholate, 5 
mM EDTA, 1% triton X-100, 0.1% SDS and 1X Protease Inhibitor Cocktail.  Cell lysates 
were scraped into Epppendorf tubes, sonicated, rotated end-over-end for 30 min at 4 oC 
and then centrifuged for 10 min to pellet insoluble material.   The protein concentration 
was determined by the Lowry method, as described in chapter III.  Lysates were either 
used immediately or frozen as single-use aliquots at -80 oC for subsequent immunoblot 
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analysis.  Lysates were separated by electrophoresis on a 4-12% gradient Bis-Tris SDS-
PAGE gel (Invitrogen, Carlsbad, CA) for 15 min at 100 V and 90 min at 120 V.  Proteins 
were transferred to 0.45 µM pore nitrocellulose for 90 min at 25 V. Membranes were 
blocked for 1 hour at 4 oC in Tris-buffered saline (25 mM Tris, 1.3 mM KCl and 137 mM 
NaCl) containing 0.1% TWEEN-20 (TBST) and 5% non-fat milk.  Blots were probed with 
primary antibody to ABCA1 (dilution 1:750)(Novus Biologicals, Littleton, CO), ABCG1 
(dilution 1:750)(GeneTex Inc, Irvine, CA), SR-BI (dilution 1:1000)(Novus Biologicals, 
Littleton, CO), apoE (dilution 1:50000)(a gift from Dr. Larry Swift, Vanderbilt University), 
or β-actin (1:5000) (Santa Cruz, Santa Cruz, CA) overnight at 4 oC and then incubated 
with horseradish peroxidase (HRP)-conjugated secondary antibodies (Promega, 
Madison, WI) for 1 hour at room temperature.  Protein bands were visualized on Kodak 
Biomax film using enhanced chemiluminescence detection methods. 
 
Results 
There are a number of potential pathways liberated FC could enter following 
release from the lysosome (figure 27). Importantly, mobilized lysosomal FC can be 
trafficked to the ER for sorting and processing, including reesterification by ACAT 
resulting in the generation of cytoplasmic CE (269,270).  In order to determine if FC is 
transported to ACAT for reesterification to form cytoplasmic CE droplets, we repeated 
our lipid loading experiments with the inclusion of the ACAT inhibitor CP113,818. The 
lysosomal sequestration that occurs following treatment with cholesterol-rich particles 
renders this sterol unavailable as a substrate for ACAT. Thus, the majority of the CE that 
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accumulates following treatment with cholesterol-rich particles is localized specifically 
to the lysosome. Consistent with our previous results, treatment with cholesterol-rich 
particles (aggLDL or CE-DISP) induced similar levels of cholesterol loading that did not 
change upon inhibition of ACAT (figures 28A and 28C).  Inhibition of ACAT had minimal 
effects on TG levels in cells treated with TG-rich lipid dispersions and/or VLDL (figures 
28B and 28D).  Additionally, inhibition of ACAT did not influence cholesterol levels in TG-
enriched cells (figures 28A and 28C).  This indicates that the cholesterol mobilized from 
lysosomes following TG-enrichment is not reesterfied by ACAT.  Thus, liberated 
lysosomal cholesterol is not stored intracellularly but, rather, is mobilized from the cell. 
FC released from lysosomal processing of endocytosed lipoproteins has been 
shown to activate ER stress (46,73,207,271). Therefore, if the massive amounts of FC 
released from lysosomes following TG enrichment is trafficked to the ER and not 
properly managed, ER stress could be activated.  Activation of ER stress can lead to the 
activation of apoptosis.  In order to determine the fate of liberated FC with respect to 
apoptotic signaling, we measured the expression of ER stress mediators following 
loading with TRPs and/or cholesterol-rich lipoproteins.  Importantly, we examined 
markers of early (phospho-eIF2α) and late (CHOP) portions of the ER stress signaling 
cascade to determine if the pathway is both initiated and advanced by liberated 
lysosomal FC.  Treatment with CE-DISP for six days (60 µg CE/ml) induced the expression 
of CHOP as well as the phosporylation of eIF2α (figure 29).   Interestingly, inclusion of 
TG-DISP in combination with CE-DISP reduces the expression of CHOP and phospho- 
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Figure 28: Accumulation of lipids in THP-1 macrophages incubated with TRPs and/or 
cholesterol-rich lipoproteins with and without the ACAT inhibitor CP113,818 (1.5 µg/ml 
medium).  THP-1 macrophages were treated for 6 days at 37°C in RPMI containing 1% 
FBS and TPA (50 ng/ml) alone or containing CE DISP (60 µg CE/ml) and/or TG DISP (50 µg 
TG/ml) or 100 µg protein/ml aggLDL and/or VLDL.  The cells were harvested and the 
cellular lipid levels were determined as described in Materials and Methods. Inhibition 
of ACAT has no effect on TG levels in cells treated with TG-rich lipid dispersions (B) or 
VLDL (D) (p>0.05). Additionally, inhibition of ACAT does not affect cholesterol loading in 
all conditions (p>0.05). Importantly, inhibiting ACAT does not change the reduction in 
cellular cholesterol observed in TG-enriched cells (A, C) (p>0.05). This indicates that 
neither the cholesterol accumulation observed with CE loading nor the mobilization by 
TG-enrichment involves increased cholesterol reesterification via ACAT. Values are the 
mean ± SEM for three experiments.  Comparisons between matched conditions (similar 
lipid loading with and without ACAT inhibitor) were not statistically significant (p>0.05) 
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Figure 29: Western blot analysis of mediators of ER stress.  Analysis of cells treated with 
CE DISP (60 µg TG/ml) with and without TG DISP (50 µg TG/ml) for 6 days shows 
differential expression of ER stress proteins CHOP and phospho-eIF2α.  Treatment with 
cholesterol-rich particles alone induced the expression of ER stress proteins including 
those expressed at late (CHOP) and early (phospho-eIF2α) stages of the ER stress 
response. Similar to previous studies, this indicates that ER stress is both initiated and 
maintained in cholesterol enriched macrophage foam cells. However, coincubation with 
TRPs reduced the expression of ER stress proteins. Fifteen micrograms of protein was 
loaded in each lane and incubation conditions were as described in Experimental 
Procedures.  
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eIF2α to control levels (figure 29), indicating the absence of ER stress in coincubated 
cells.  
The absence of ACAT reesterification and lack of ER stress following TG 
enrichment suggests that FC liberated from lysosomes could be rapidly transported to 
the PM for cholesterol efflux. Moreover, our results not only show that lysosomal 
clearance of sterol (FC and CE) is accentuated with TRP treatment but also indicate a 
decrease in total cellular cholesterol levels. Surprisingly, this occurs even in the absence 
of exogenously added extracellular cholesterol acceptors. Thus, cellular cholesterol 
mobilization occurred in media containing only 1% serum (chapter III, figure 7 and 
figure 9) and also in serum free media (figure 30).  The efflux of cholesterol from the cell 
could occur through a number of processes including both passive cholesterol diffusion 
from the plasma membrane to the surrounding media or through active processes, 
including those mediated by ABCA1, ABCG1, SR-BI and/or apoE. Many of these, 
however, require extracellular acceptors for maximal efflux.  In order to define the 
mechanism of cholesterol efflux in TG-enriched macrophages, we examined cellular 
protein levels of ABCA1, ABCG1, SR-B1 and ApoE by western blot.  Compared to non-
loaded control cells, no differences were observed in the protein levels of ABCA1, 
ABCG1 and SR-B1 in TG-enriched cells (figure 31).  However, coincubation of cells with 
VLDL and aggLDL resulted in a drastic reduction in cell-associated apoE protein levels 
(figure 31).  We reason that this is likely due to secretion of apoE from the cell. This is a 
potentially important finding because, following its release from the cell, secreted apoE 
can mediate the efflux of cholesterol. Thus, it is plausible that apoE released from  
125 
 
 
 
 
 
 
 
Figure 30:  Accumulation of lipids in THP-1 macrophages incubated with aggLDL and/or 
VLDL in serum free media. THP-1 macrophages were treated for 6 days at 37°C in 
macrophage serum free media and TPA (50 ng/ml) alone or with 100 µg protein/ml of 
aggLDL and/or VLDL. The cells were harvested and the cellular lipid levels were 
determined as described in Materials and Methods. A: Incubation of THP-1 
macrophages with aggLDL produced a significant increase (p<0.01) in total cholesterol, 
free cholesterol (dark gray portion of the bar) and esterified cholesterol (light gray 
portion of the bar). Incubation with both aggLDL and VLDL significantly reduced the 
cellular CE accumulation compared to that seen with aggLDL alone (p<0.01). B: 
Incubation of cells with VLDL produced a significant increase in cellular TG levels 
compared to control or aggLDL-treated cells both when used alone or in combination 
with aggLDL (p<0.001).  Treatment of macrophages in SFM are similar to the results 
achieved in cells treated in 1% FBS (figure 7), indicating that the serum concentration of 
the media does not affect lipid loading. Values are the mean ± SEM for three 
independent experiments.   
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Figure 31: Western blot analysis of key mediators of cholesterol efflux.  THP-1 
macrophages were treated for 6 days with VLDL and/or aggLDL (50 µg lipoprotein/ml). 
Compared to non-loaded control cells, no differences were observed in the protein 
levels of ABCA1 (A), ABCG1 (A) and SR-B1 (B) in TG-enriched cells. Coincubation of cells 
with VLDL and aggLDL resulted in a drastic reduction in cell-associated apoE protein 
levels (C), indicating that apoE could be secreted from the cell where it could serve as an 
extracellular cholesterol acceptor. 
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lysosomes following TG enrichment could act as an extracellular cholesterol acceptor (as 
diagrammed in figure 32). 
 
Discussion: 
 The current studies suggest that FC liberated from lysosomes following TG 
treatment of foam cells is trafficked to the PM for efflux and does not contribute to 
intracellular cholesterol signaling.  Previous studies have shown that FC liberated from 
lysosomes can be trafficked to the ER for processing (207) (figure 27).  In foam cells, this 
massive movement of cholesterol into the ER, the site of cholesterol homeostatic 
enzymes, could initiate signaling pathways to process cytotoxic FC into an inert form for 
storage in a process catalyzed by the enzyme ACAT.  The absence of ACAT-derived CE in 
our TRP treated cells suggests that following its release, lysosomally sequestered 
cholesterol is not trafficked to the ER.  This is supported by the absence of ER stress 
signaling that occurs following FC enrichment of ER membranes. Recent studies suggest 
that trafficking of lysosomally processed FC to the ER contributes to the activation of ER 
stress (46,73,207,271). However, we do not observe activation of ER stress following TG-
induced liberation of lysosomal cholesterol.  The absence of ACAT reesterification and 
activation of ER stress in combination with the massive reduction in cellular cholesterol 
upon TG-enrichment suggests that sterol mobilized from lysosomes following treatment 
with TRPs is rapidly transported to the PM for efflux. 
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Figure 32: Diagram of the metabolism of apolipoprotein E (apoE).  ApoE is an important 
mediator of cholesterol homeostasis.  Macrophages are able to synthesize apoE.  
Additionally, macrophages can acquire apoE from exogenous sources, including from 
endocytosed apoE-containing lipoproteins, such as VLDL. ApoE derived from 
lipoproteins can escape degradation in the lysosome and be recycled to the cell surface 
where it can act as an acceptor of effluxed cholesterol. 
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As mentioned previously, exposure of foam cells to promoters of cholesterol 
efflux is not sufficient to mobilize lysosomal cholesterol (13).  Therefore, TRPs must 
exhibit multiple effects on the mobilization of macrophage cholesterol including the 
restoration of lysosomal function, enhanced lysosomal sterol hydrolysis, mobilization of 
lysosomal sterol to the PM and promotion of efflux from the cell.  The analysis of the 
major pathways of cholesterol efflux presented in this chapter suggests an important 
role for apoE in the removal of cholesterol from TG-enriched foam cells. Cell-associated 
apoE is reduced in cellular fractions of macrophages coincubated with aggLDL and VLDL, 
suggesting that apoE is secreted and, as a result, is able to mediate the removal of 
cholesterol from the TG-enriched macrophages.  This is consistent with previous studies 
showing that endogenous apoE plays a critical role in cholesterol efflux from 
macrophages (110,112,272-276).  Specifically, in vitro studies show that induction of 
apoE expression in cultured macrophages enhances cholesterol efflux, even in the 
absence of other extracellular cholesterol acceptors (110). Furthermore, exogenous 
apoE could contribute to the cholesterol mobilization observed in TRP-treated 
macrophages. ApoE is an important apoprotein component of TRPs, including VLDL 
(277,278).  Previous studies show that apoE acquired from exogenous sources, such as 
internalization as a component of VLDL, is spared degradation in the lysosome and is 
recycled to the to the extracellular space, where it can act as a cholesterol acceptor 
(177,279-289). Thus, apoE recycled from endocytosed VLDL may be important in 
inducing cholesterol removal in TG-enriched foam cells.  Although further studies are 
required in order to distinguish the contribution(s) of exogenous versus endogenous 
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apoE in the TG-induced cholesterol mobilization, the studies shown here suggest a 
significant role of apoE in cholesterol efflux of mobilized lysosomal sterol. 
Surprisingly, we did not see an upregulation of protein expression for other 
efflux promoters (including ABCA1, ABCG1, and SR-BI) following TG enrichment. The 
expression of these promoters is regulated by LXR gene expression, which can be 
activated by FA, such as those generated by TRP hydrolysis and FFA found in the 
circulation (290-296).  ABCA1 and ABCG1 are transmembrane proteins that utilize the 
energy released from ATP-hydrolysis to transport PLs and cholesterol across the plasma 
membrane to their acceptors, lipid-poor apoA1 and nascent HDL, respectively 
(72,107,109,297).  However, there is crossreactivity between cholesterol efflux 
pathways which could significantly impact cholesterol efflux to apoE.  For example, 
ABCA1 can transfer lipids to apoE, and SR-BI can mediate cellular levels and secretion of 
apoE (274,298,299). Therefore, it is possible that TG-enrichment enhances the activity 
of efflux promoters without changing their protein expression.  
Future studies should specifically measure the activity of ABCA1, ABCG1 and SR-
BI in TG-enriched and/or cholesterol-enriched macrophages. Specifically, studies should 
be performed in the presence of cholesterol acceptors, including apoA1 and nascent 
HDL to examine the transfer of cholesterol through ABCA1, ABCG1 and SR-BI mediated 
pathways. ABCA1 effluxes cholesterol to lipid-poor apoproteins including apoA1 (300).  
Therefore, if activity of ABCA1 is increased in the presence of TG, there should be 
measureable efflux to apoA1.  
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Measurement of the activity of ABCG1 and SR-BI is more complex because both 
transporters efflux cholesterol to the same acceptor: nascent HDL.  Therefore, to 
analyze the activity of each efflux promoter individually, studies must be performed 
using specific inhibitors of each pathway in the presence of nascent HDL. The activity of 
SR-BI can be inhibited by treatment with the inhibitor block lipid transport-1 (BLT-1) 
while the activity of ABCA1 can be inhibited by treatment with cyclosporin A (301,302).  
Since the studies shown in this chapter suggest that apoE is the mediator of cholesterol 
efflux, studies examining ABCA1, ABCG1 and SR-BI activity should be perfomed with 
THP-1 macrophages that have been treated with apoE siRNA constructs.  Comparison of 
this cell line to normal THP-1 macrophages will allow us to determine the role of apoE in 
the efflux of cholesterol through each lipid transporter.  
Our current data strongly suggests that, in the presence of intracellular TG, 
cholesterol mobilized from the lysosome is removed from the cell through active 
cholesterol efflux mechanisms involving apoE.  The results indicate that in addition to 
improving the ability of the foam cell to process endocytosed cholesterol, TG can induce 
efflux of liberated cholesterol.  Therefore, TG or its metabolites significantly improve the 
ability of macrophage foam cells to mobilize intracellular cholesterol to efflux pathways. 
Accordingly, TG has the potential to greatly improve atherosclerotic lesion regression. 
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CHAPTER VII. 
 
 
 
SUMMARY, DISCUSSION AND FUTURE DIRECTIONS: 
TRIGLYCERIDE-RICH PARTICLES MAINTAIN LYSOSOME ACTIVITY, MOBILIZE 
LYSOSOMAL CHOLESTEROL AND ENHANCE THE EFFLUX OF CHOLESTEROL FROM 
MACROPHAGE FOAM CELLS IN A TRIGLYCERIDE DEPENDENT MANNER 
 
  
 
The studies presented in this dissertation probe the complex interactions 
between lipids and macrophage foam cells.  A majority of previous studies focused on 
the effects of a single lipid species (i.e. cholesterol) in macrophage foam cell formation 
and do not consider the intricate relations between the variety of lipoproteins and 
extracellular lipids found within the lesion.  The presence of other lipids can clearly 
influence macrophage cholesterol metabolism and as shown by our studies can induce 
reverse cholesterol transport from foam cells.  Previous studies using genetic 
manipulation of intracellular cholesterol metabolism show that enhanced clearance of 
cholesterol from foam cells initiates lesion regression (50).  However, in clinically 
important lesions, greater than 70% of the sterol within a foam cell is trapped within 
lysosomes and unavailable to reverse cholesterol transport mechanisms (5,13,125,205).  
To date very little progress has been made in the discovery of treatments that would 
mobilize cholesterol from the lysosome. Our finding that significant mobilization of 
lysosomal cholesterol occurs following TG treatment is a groundbreaking discovery that 
could prove to be significant in lesions as a means to increase reverse cholesterol 
transport as well as influence lesion remodeling and regression.  
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Intracellular TG Mobilizes Lysosomal and Cellular Cholesterol 
The data presented in this dissertation suggest that intracellular TG elicits a 
principal influence on lysosomal and cellular cholesterol homeostasis. While the 
magnitude of the effect varies based on cell passage number and the source of 
lipoproteins we consistently see an increase in cellular TG following treatment with TRPs 
that results in a decrease in cellular and lysosomal cholesterol levels. This effect is not 
due to competition between cholesterol-rich and TG-rich particles for uptake; however, 
it appears to be directly related to the concentration of TG within the cell.  Furthermore, 
the studies in chapter III show that by altering lysosomal cholesterol content TG restores 
and/or prevents the loss of lysosomal v-ATPase activity, which is a novel finding.  
The effect of TG on the metabolism of lysosomal and cellular cholesterol is 
clearly more complex than we initially anticipated. Our studies establish a novel 
relationship between intracellular TG levels and cholesterol mobilization. However, 
additional studies are required to ascertain the specific details of the intracellular 
interactions of the two lipids. For example, the relative contributions of lysosomal 
versus cytoplasmic TG to the effects on cellular cholesterol mobilization remain unclear. 
TG can accumulate in cells through two distinct pathways: surface hydrolysis of TRPs 
followed by uptake of FAs and reesterification back to TG within the cell cytoplasm 
and/or receptor-mediated endocytosis of particles (chapter V, figure 26).  Consistent 
with previous reports, FAs generated by LPL-mediated surface hydrolysis of VLDL are 
rapidly resynthesized into cellular TG in our THP-1 macrophage foam cells. In contrast, 
TG-DISPs, which are representative of the extracellular lipid pools found within an 
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atherosclerotic lesion, are not affected by surface LPL hydrolysis.  Rather, these particles 
are engulfed through the endosomal-lysosomal system and the TG accumulation from 
this mechanism is solely dependent on lysosomal processing of the particles. The 
disparate pathways through which various TRPs enter the cell suggest that within the 
TG-enriched foam cell there are distinct intracellular pools of TG and FAs that can affect 
lysosomal and cellular cholesterol metabolism. An important concern to be addressed in 
the future is to ascertain the differences and similarities in the ability of these 
intracellular pools to modulate intracellular cholesterol metabolism. 
While the studies presented in this dissertation make significant progress in 
defining a mechanism for the influence of TG on macrophage cholesterol homeostasis a 
specific mechanism has not been conclusively identified.  At least four distinct pools of 
TG and/or the proteolytic byproducts of TG could be involved in the mobilization of 
lysosomal and cellular cholesterol, including lysosomal TG, cytoplasmic TG, lysosomally 
generated FAs, and/or surface-generated FAs. For example, accumulation of lysosomal 
TG could change the physical properties of the lipids within the lysosome, rendering 
them more amenable to hydrolysis by lysosomal lipases.  Similarly, generation of FA by 
lysosomal and/or surface hydrolysis of TG would introduce potent activators of lipid 
homeostatic genes and could enhance the mobilization of lysosomal and cellular 
cholesterol.  Future studies should explore the contribution of lysosomal versus 
cytoplasmic TG in the mobilization of lysosomal cholesterol.  One potential experimental 
strategy would be to treat cells with a nondegradable triether analogue of TG, 
trialkylglycerol ether (TGE), to determine the significance of TG hydrolysis and 
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resynthesis on sterol metabolism (303,304).  TGE could be delivered to the cell as a 
component of TG-DISPs and, since it is not hydrolytically cleaved by LPL or LAL, it would 
be delivered to the lysosome where it would accumulate due to the lack of hydrolysis. 
Additionally, substrates for intracellular TG synthesis (i.e. glycerol and FAs) would not be 
generated because TGE is not hydrolyzed and, as a result, treatment with TGE would 
serve as a negative control for TG resynthesis. Therefore, by employing TGE we would 
be able to determine the influence of lysosomal TG versus cytoplasmic TG pools on 
cholesterol clearance.  We anticipate that multiple intracellular pools of lipid contribute 
to the mobilization of lysosomal and cellular cholesterol since treatment with TG-DISP, 
VLDL and FAs exhibit similar effects on cholesterol homeostasis in spite of distinct 
uptake and processing mechanisms for each molecule.  
 The ability of TG to alter lysosomal function is significant. Recent studies suggest 
lysosomes are critical mediators of intracellular lipid metabolism extending far beyond 
their role in lipoprotein endocytosis (305-307).  A newly defined autophagic process, 
known as macrolipophagy is responsible for the degradation of intracellular lipid 
deposits. Macroautophagy is a conserved process that allows the cell to repair itself by 
degrading cytoplasmic components, including long-lived proteins and excess or 
dysfunctional organelles (308). The process involves the sequestration of cytoplasmic 
material within a double-membrane vesicle and fusion of the vesicle with lysosomes to 
degrade the faulty material (308). However, recent studies by Singh et al. show the 
recruitment of LC3 and other autophagy related proteins to lipid droplets, where they 
form a double membrane autophagosome structure that encloses portions of 
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intracellular lipid droplets (figure 33)(305).  Similar to macroautophagy, the newly 
formed autophagosome delivers these sequestered portions of the cytoplasmic lipid 
droplets to the lysosome for degradation (305). While macrolipophagy has only been 
examined in hepatocytes it could prove to be a very important process in macrophage 
lipid homeostasis (figure 33).  The inability of macrophages to mobilize intracellular 
lipids results in the formation of foam cells.  If macrolipophagy is active in macrophage 
foam cells inert cytoplasmic lipid droplets could be redistributed to the lysosome for 
processing and clearance. Importantly, macrolipophagy is activated by cellular TG 
enrichment.  Thus, the ability of TRPs to mobilize lysosomal cholesterol in a TG-
dependent manner could be partially related to the activation of macrolipophagy in 
foam cells.  Future studies examining the expression of markers of macrolipophagy in 
relationship to intracellular lipid deposits in TG-enriched foam cells will be highly 
relevant. 
 
Triglyceride Increases Lysosomal Membrane Fluidity 
 We previously showed that increased cholesterol in lysosome membranes can 
disrupt lysosomal function by inhibiting lysosomal v-ATPases (10). In this dissertation, 
we have extended these studies to show that increasing intracellular TG restores 
lysosomal v-ATPase activity, and this occurs in relation to an increase in the fluidity of 
lysosomal membranes (chapters III and IV).  While the concept of lipoprotein-derived 
lipids altering membrane fluidity is not novel the studies presented in this dissertation 
are the first to show changes in lysosomal membrane fluidity following TG and/or 
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Figure 33: The potential role of macrolipophagy in macrophage foam cells.  
Macrolipophagy was recently identified to play a critical role in intracellular lipid 
metabolism in hepatocytes.  In this process, portions of intracellular lipid droplets are 
sequestered in autophagosomes and delivered to the lysosome for processing. While 
this process is newly discovered to contribute to a significant portion of the lipid 
turnover in hepatocytes it could play an even more significant role in foam cells, where 
the lipid burden is often too great for hydrolytic enzymes, including NCEH, to 
compensate. 
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cholesterol enrichment in macrophage foam cells. Importantly, the fluidity of the 
lysosomal membrane is closely related to lysosomal function.  Thus, alterations in 
lysosomal lipid content can significantly impact the capacity of the lysosome to degrade 
endocytosed material.  
 Our studies suggest that, at least in foam cell lysosomes, cholesterol plays a 
more prominent role in determining membrane fluidity than the PL acyl side-chain 
composition.  The increase in lysosomal membrane cholesterol content is likely too 
great for the cholesterol-enriched foam cell to completely compensate for through 
normal processes. However, our data suggests that manipulation of the lysosomal 
membrane fluidity could significantly improve the ability of foam cells to mobilize 
intracellular cholesterol.  The ability of TG to influence membrane fluidity could have 
important implications in other cellular organelles, including the ER.  In addition to 
reducing the sterol content of foam cell lysosomes, TG mobilizes total cellular 
cholesterol resulting in increased efflux.  Presumably this reduction in cellular 
cholesterol content could impact the cholesterol content of all organelle membranes, 
including the ER. Previous studies show that the inhibition of SERCA2b, the ER calcium 
pump responsible for maintaining ER calcium stores, occurs in relation to an increase in 
ER cholesterol (207).  The loss of SERCA2b activity following FC enrichment leads to the 
depletion of ER calcium stores and results in the induction of ER stress and, ultimately, 
foam cell apoptosis. Therefore, reducing the FC content of the ER membrane in foam 
cells would restore SERCA2b activity, prevent the activation of ER stress and reduce FC-
mediated foam cell death. Accordingly, we show a reduction in the expression of 
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mediators of ER stress in response to TG enrichment (Chapter VI, Figure 29).  One 
interpretation of these results shown here is that TG is able to reduce the cholesterol 
content of all organelle membranes by promoting the mobilization of cholesterol from 
foam cells.  In this regard, TG enrichment might reverse or prevent FC accumulation in 
the ER and, as a result, eliminate macrophage apoptosis via ER stress mechanisms.  The 
potential for TG enrichment to induce cell wide changes in membrane fluidity suggests 
that the effect of TG on foam cells extends far beyond alterations in lysosomal lipid 
processing. Future studies are required to explore this hypothesis. 
 
Cholesterol Efflux Following Macrophage TRP Exposure Occurs via Apolipoprotein E 
 The essential first step in the mobilization of cholesterol from macrophage foam 
cells in late stage lesions is the movement of cholesterol from the lysosome 
(5,13,125,205). Accordingly, the studies in this dissertation show that TRPs can mobilize 
lysosomal sterol. Our studies also demonstrate the massive mobilization of cholesterol 
from the macrophage following enrichment with TRPs. While release of cholesterol 
from the lysosome will make sterol available to a number of cellular pathways, the 
mobilized cholesterol must be transported to and across the PM to an acceptor in the 
surrounding media in order to be effluxed from the foam cell. The most efficient 
cholesterol efflux mechanisms involve active transport of cholesterol out of the cell. In 
the presence of TRPs, cholesterol efflux promoters are likely activated in order to 
initiate reverse cholesterol transport.  Preliminary results indicate that most known 
sterol trafficking and efflux pathways are unaffected by TG enrichment. However, levels 
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of cell-associated apoE are decreased following TG-enrichment, leading us to propose 
that apoE-dependent pathways may be the major mechanism in the TG-induced 
clearance of cholesterol following release from the lysosome. Future studies will focus 
on defining the relationship between intracellular TG, apoE uptake, synthesis and/or 
secretion and the ability of TRPs to induce cholesterol mobilization. Importantly, 
measurement of apoE protein levels in the media should be performed following 
treatment with TRPs to verify increased apoE secretion following TG enrichment. 
Additionally, further analysis is required to define the contribution of endogenous (i.e. 
synthesized) apoE and exogenous (i.e. VLDL-derived) apoE in the removal of cholesterol 
from TG-enriched macrophages. An experimental strategy to address the role of 
exogenous apoE in the effects of TG on foam cell cholesterol mobilization would be to 
silence apoE expression in THP-1 macrophages using siRNA technology.  This would 
eliminate the contribution of endogenously synthesized apoE. Exogenous apoE could be 
delivered to the cells as a component of VLDL.  Since treatment with protein-free TG-
DISPs is able to induce cholesterol efflux to a similar extent as VLDL, exogenous apoE is 
not likely to contribute significantly to the mobilization of cellular cholesterol.  Thus, we 
hypothesize that increased endogenous apoE synthesis and/or secretion plays the 
predominant role in the mobilization of cellular cholesterol following TG enrichment.   
The specific relationship between increased foam cell TG and increased synthesis 
and/or secretion of apoE is not clear. Similar to ABCA1 and ABCG1, the expression of 
apoE is controlled by the nuclear receptors LXRα and LXRβ (309). Since the transcription 
of ABCA1, ABCG1 and apoE are controlled by the same regulatory pathways involving 
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LXR, the absence of changes in ABCA1 and ABCG1 expression following TG enrichment 
suggests that apoE expression is not modified.  Therefore, it is possible that TG may 
enhance uptake/and or secretion of apoE rather than increasing its synthesis.  
Interestingly, previous studies show that OA treatment can enhance the secretion of 
apoE from macrophages (181,310). OA specifically modulates the post-translational 
glycosylation of apoE in the Golgi, which significantly increases apoE stability and 
secretion (181,311). This suggests that the FA generated by TRP hydrolysis could 
promote the secretion of endogenously synthesized apoE and as a result it enhances the 
mobilization of cellular cholesterol from TG-enriched foam cells.  
Alternatively, the decrease in cell-associated apoE following TG enrichment 
could indicate that macrophages synthesize and secrete apoE-containing lipoprotein 
particles in order to facilitate the transport of lipids to the liver for excretion.  The 
assembly of apoE containing particles by macrophages could occur through a 
mechanism similar to the assembly and secretion of VLDL by hepatocytes. Briefly, in 
hepatocytes, microsomal triglyceride transfer protein (MTP) transfers neutral lipids to 
nascent apoB (312,313) (figure 34A). MTP continues to add TG to the growing 
lipoprotein particle, resulting in the assembly of mature VLDL, which is secreted into the 
circulation. Importantly, macrophages express the enzymes required for lipoprotein 
assembly, including MTP (Dr. Larry Swift, personal communication).  Accordingly, 
previous studies have shown that macrophages are able to secrete apoE-lipid complexes 
in response to increased intracellular lipid concentration (110,314). It is possible that the 
increase in cellular TG observed in our TRP-treated macrophages stimulates MTP to 
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Figure 34: Lipoprotein assembly in hepatocytes and macrophages. A: VLDL is assembled 
in hepatocytes through the activity of MTP, which sequentially transfers neutral lipid 
first to nascent apoB and then to the precursor lipoprotein. B: Macrophages could 
potentially assemble and secrete apoE-containing lipoproteins in response to increased 
cellular TG following TRP treatment. The process could proceed similar to hepatocytes, 
with MTP transferring neutral lipid to apoE synthesized by the macrophage. 
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transfer cellular lipids to newly synthesized apoE (figure 34B).  Thus, the assembly and 
secretion of apoE-containing lipoproteins from macrophages could be an additional 
mechanism through which TG reduces foam cell cholesterol and contributes to reverse 
cholesterol transport. 
 
FA Induce Cholesterol Mobilization in a TG-dependent Manner 
The studies shown in chapter V suggest that monounsaturated and 
polyunsaturated FAs are able to replicate the effects of TRPs on cellular cholesterol 
mobilization. However, the reduction in cellular cholesterol occurs concurrently with an 
increase in cellular TG.  Accordingly, treatment with PA, a FA that is not readily 
incorporated into cellular TG, mobilizes lysosomal cholesterol but does not induce 
cellular cholesterol efflux. This emphasizes that intracellular TG synthesis is important in 
the ability of TRPs and FAs to mobilize cellular cholesterol. Additionally, while the 
studies presented here show that FA treatment is able to reduce cellular cholesterol 
levels, it will be important to examine the effects of particular FAs on the lysosome in 
future studies. Specifically, it will be important to verify that FA supplementation 
restores lysosome function and enhances lysosomal cholesterol clearance.  The results 
of these future studies have significance in specifically identifying the role of FAs and/or 
intracellular TG levels on cholesterol homeostasis.  Understanding the complex 
interactions between lipids within the macrophage is crucial in developing therapeutic 
strategies to induce reverse cholesterol transport from atherosclerotic foam cells. 
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The preliminary studies presented here establish the ability of specific FAs to 
mobilize cellular cholesterol from macrophage foam cells.  In order to define more 
clearly the contribution of FAs to the effects on cholesterol mobilization it will be 
necessary to examine the effects of other common dietary FAs on foam cell cholesterol 
homeostasis including saturated, monounsaturated and polyunsaturated FAs of various 
chain lengths (table 6).  Stearic acid (SA) would be the most logical saturated FA to 
analyze since it is poorly incorporated into TG and does not induce apoptosis as 
dramatically as PA (315-317). SA is a reasonable choice since it would present a 
saturated FA similar to PA and is less cytotoxic than PA. However, one limitation to the 
use of SA as a representative saturated FA is that SA is rapidly converted to OA by 
stearoyl-CoA desaturase (SCD) following internalization (318,319). Therefore, 
experiments with SA would need to be performed in the presence of SCD inhibitors, 
including sterculate (320).   
An important class of FAs are those derived from fish oils. It would be 
informative to determine if the PUFAs found in fish oils, including eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA), are able to reproduce the effects of OA and LA 
on cellular cholesterol homeostasis. Current dietary recommendations of the American 
Heart Association suggest that dietary supplementation of EPA and DHA, either through 
consumption of fish two times a week or through fish oil capsules, leads to lower 
cardiovascular risk (321).  Thus, part of the ability of EPA and DHA to reduce 
cardiovascular risk may be due to the cholesterol mobilization effects presented in this 
dissertation.  Examination of the effects of additional dietary fatty acids on the 
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Table 6: Most common dietary fatty acids. Future studies are required to define the role 
of dietary FAs in foam cell cholesterol mobilization. The FAs listed here are the most 
common FAs found in the average American diet. Information compiled from the 
International Food Information Council at http://www.ific.org/. 
 
Common Name # of 
Carbon 
Atoms 
# of 
Double 
Bonds 
Structure Dietary 
Source 
Common Saturated FAs 
Caproic Acid 6 0 CH3(CH2)4COOH  
Butterfat, 
Coconut Oils 
Caprylic Acid 8 0 CH3(CH2)6COOH 
Capric Acid 10 0 CH3(CH2)8COOH 
Lauric Acid 12 0 CH3(CH2)10COOH 
Myristic Acid 14 0 CH3(CH2)12COOH 
Palmitic Acid 16 0 CH3(CH2)14COOH Cottonseed, 
Palm Oils 
Stearic Acid 18 0 CH3(CH2)16COOH Cocoa 
Butter, 
Animal Fat 
Arachidic Acid 20 0 CH3(CH2)18COOH Peanut Oil 
Common Unsaturated FAs 
Palmitoleic Acid 16 1 CH3(CH2)5CH-CH(CH2)7COOH Fish Oils,  
Beef Fat 
Oleic Acid 18 1 CH3(CH2)7CH=CH(CH2)7COOH Olive Oil, 
Canola Oil 
Linoleic Acid 18 2 CH3(CH2)4(CH=CHCH2)2(CH2)6COOH Soybean Oil,  
Corn Oil 
α-Linoleic Acid 18 3 CH3(CH2)4(CH=CHCH2)3(CH2)6COOH Soybean Oil,  
Canola Oil 
Arachidonic 
Acid 
20 4 CH3(CH2)4(CH=CHCH2)4(CH2)2COOH Lard 
EPA 20 5 CH3CH2(CH=CHCH2)5(CH2)2COOH Fish Oils 
DHA 22 6 CH3CH2(CH=CHCH2)6(CH2)COOH Fish Oils 
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mobilization of intracellular foam cell cholesterol would broaden our knowledge of the 
relationship between circulating dietary lipids and atherogenesis. 
Despite initial evidence suggesting that TG plays a more significant role than FA 
in influencing the reduction of cellular cholesterol, the data presented here do not 
conclusively rule out the potential for transient effects of FA on cholesterol metabolism. 
Given the rapid turnover of TG, the important effects of TG on the foam cell may be the 
result of cholesterol flux through the cell rather than cellular TG accumulation. Thus, it is 
possible that short term exposure to FAs generated by hydrolysis of TRPs could activate 
cell signaling pathways that alter cellular sterol metabolism prior to their incorporation 
into cellular TGs.  Studies using inhibitors of cellular TG synthesis could address this 
possibility.  Triacsin C, an inhibitor of long-chain fatty acyl CoA synthetase, blocks the de 
novo synthesis of TG, CE and diglycerides.  Our preliminary studies show that triacsin C 
inhibits the incorporation of FAs into all cellular lipids and, as a result, is not useful in 
distinguishing FA versus TG effects on cholesterol metabolism.  However, use of specific 
inhibitors of TG synthesis, including inhibition of DGAT, the key enzyme catalyzing the 
final step in known pathways of TG synthesis, could specifically examine the role of TG 
synthesis in effects on cellular cholesterol homeostasis.  This could prove to be difficult 
due to the lack of synthetic inhibitors of DGAT.  In vitro studies have identified several 
naturally occurring compounds that have potent DGAT inhibitory properties including 
xanthohumols, roselipins, prenylflavonoids, polyacetylenes and tanshinones (322-326).  
Additionally, siRNA technology could be used to knock down the expression of DGAT in 
the THP-1 macrophage cell line.  In DGAT silenced cells, FAs would not be utilized for TG 
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synthesis and, as a result, we would be able to determine the significance of TG 
synthesis in the mobilization of lysosomal and cellular cholesterol from foam cells.  
Defining the contribution of TG and FAs in cholesterol homeostasis is important to 
design effective therapies to modulate reverse cholesterol transport in macrophage 
foam cells. 
 
Potential Therapies Involving Alterations in Lesion TRPs and FAs 
The studies presented in this dissertation suggest TG has the potential to induce 
reverse cholesterol transport and, as a result, can promote lesion regression.  
Importantly, high TG levels are correlated to some diseases including obesity and 
diabetes. Therefore, systemic increases in TG could be detrimental. However, 
specifically increasing TG levels within the atherosclerotic lesion may prove to have a 
therapeutic benefit.  Cancer biologists have utilized homing mechanisms to tumors in 
order to specifically target the tumor for drug delivery, therapeutic moieties, and 
imaging agents (327-329).  Such homing strategies are based on disease-specific 
molecular tags expressed in the vasculature, which is referred to as a vascular ‘zip code’ 
system (327-329).  Pathological hallmarks of atherosclerotic lesion vasculature, mainly 
the dysfunction of endothelial cells, are currently being studied for their vascular 
homing properties (330-332).  Recent studies have identified targeting moieties that 
home specifically to the developing atherosclerotic plaque. Using phage display in vivo 
biopanning, Thapa et al. have discovered a novel peptide (CLWTVGGGC) that is 
specifically targeted to the atherosclerotic endothelium (332). Once delivered to the 
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lesion the peptide is able to deliver attached cargo, including fluorescent tracers, into 
the subendothelial space (332).  Thus, conjugation of an artificial TG particle, similar to a 
TG-DISP, to the targeting peptide would allow the specific delivery of TG to the interior 
of the atherosclerotic lesion (figure 35). Although utilizing such mechanisms for 
atherosclerotic lesion regression could take years to develop, the delivery of TG to the 
lesion using such mechanisms could clearly have an important therapeutic benefit.  In 
the short term, utilization of homing peptides to deliver TRPs to the artery wall could be 
a tool to investigate the effects of TG on lesion regression in vivo using mouse models of 
atherosclerosis.  Such in vivo studies defining the role of TG in foam cell cholesterol 
homeostasis within the atherosclerotic lesion would be highly relevant. 
Importantly, the studies shown here reveal that unsaturated FAs are also able to 
induce reverse cholesterol transport.  Therefore, FA supplementation could be a more 
promising alternative for therapy, given their ability to reduce a number of 
atherosclerotic risk factors.  Current dietary recommendations of the World Health 
Organization and American Heart Association suggest substitution of PUFAs for 
saturated FAs as part of a healthy diet that reduces the risk of developing coronary 
heart disease (321,333,334).  Dietary supplementation with fish oil, which contains the 
omega-3 PUFAs EPA and DHA, reduces the incidence of cardiac death by 30 – 45% 
(321,335,336). Furthermore, mono- and polyunsaturated FAs have the ability to lower 
serum total and LDL-cholesterol levels (337-339).  An increase in dietary n-3 PUFAs is 
known to increase macrophage cholesterol efflux by altering the physical state of 
cholesterol within the cell and increasing CE hydrolysis, as well as increasing the fluidity 
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Figure 35: A potential therapeutic strategy involving directed TG delivery to the 
atherosclerotic lesion. While systemic increases in TG could have potentially harmful 
side effects the targeted delivery of TG to the atherosclerotic lesion could result in 
macrophage foam cell cholesterol efflux and, as a result, lesion regression.  Peptides 
that specifically deliver molecules, including drugs and fluorescent imaging probes, are 
currently in development.  Initial studies suggest that peptides designed to recognize 
the dysfunctional endothelial cells that overlay an atherosclerotic lesion deliver cargo 
specifically to the subendothelial space. Utilization of this technology could prove useful 
in delivering TG to the lesion, which could initiate reverse cholesterol transport from 
atherosclerotic foam cells by similar mechanisms to those defined in this dissertation. 
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of cellular membranes (227,340,341). Additionally, FA supplementation has been shown 
to produce anti-inflammatory effects (342). Thus, the potential of FAs to enhance 
lysosomal sterol movement to pathways responsible for reverse cholesterol transport, 
as suggested by the studies in this dissertation, could prove to be another therapeutic 
benefit of FA supplementation. 
Consistent with our studies dietary FAs, including OA, have been shown to 
contribute to lesion regression (343).  Previous studies performed in Golden Syrian 
Hamsters exhibiting advanced atherosclerotic lesions showed that switching dietary 
lipids from a saturated (e.g. coconut oil) to monounsaturated (e.g. olive oil) composition 
results in dramatic reduction in aortic arch lesion area which is consistent with 
enhanced lesion regression (343). The effects of altered circulating FA on lesion 
regression appear to be partially mediated by the ability of MUFAs and PUFAs to reduce 
circulating LDL levels. However, clinical studies examining the effects of FA 
supplementation and/or dietary changes on lesion regression have not examined the 
potential for FA to influence the individual components of the lesion, including the 
potential for FA supplementation to mobilize foam cell sterol.  Consequently, studies in 
primates show reduction of coronary artery atherosclerosis following dietary 
supplementation with polyunsaturated FA that occurs independently from affects on 
circulating lipoproteins (344). PUFA supplementation has also been shown to reduce 
cardiovascular disease independently of effects on serum cholesterol in human 
populations (333,345).  Dietary consumption of PUFAs is associated with a reduction in 
arterial stiffness, which is thought to occur due to the ability of PUFAs to alter the 
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structural properties of the atherosclerotic lesion (346).  The PUFA-induced reduction in 
arterial stiffness suggests that a diet high in PUFAs could prevent the calcification and 
loss of elasticity present in advanced atherosclerotic lesions. Although the effectiveness 
of DHA and EPA in mobilizing foam cell lysosomal and cellular cholesterol must be 
examined the promising preliminary results achieved following treatment with OA and 
LA suggest that a portion of the lesion regression and remodeling observed following 
PUFA treatment in vivo is due to the mobilization of foam cell cholesterol (figure 36). 
Thus, the studies presented here establish a potential mechanism for the observed 
benefit of FA supplementation on atherosclerotic lesion regression. 
 
Closing 
Clinical studies examining the influence of circulating lipid profiles and risk of 
cardiovascular disease suggest high plasma TG levels are a risk factor for atherosclerosis.  
However, the relationship between hypertriglyceridemeia and atherogenesis remains 
undefined and highly controversial.  The work presented here argues in favor of TG 
having positive effects on atherosclerosis. TG significantly mobilizes lysosomal 
cholesterol and is the only molecule shown to do so to date.  Considering that over 70% 
of the cholesterol in late-stage atherosclerotic macrophage foam cells can be trapped in 
lipid engorged lysosomes, the influence of TG on intracellular cholesterol metabolism is 
extremely important.  Not only does TG increase the clearance of lysosomal cholesterol 
but enrichment of macrophages with TG enhances mobilization of extralysosomal 
cholesterol as well.  Therefore, the results of our studies provide strong evidence that 
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Figure 36: The potential therapeutic value of PUFA supplementation. We have 
established a role for PUFAs in mobilizing foam cell cholesterol in vitro. Given the ability 
of PUFAs to induce the release of sequestered lysosomal sterol and efflux of cholesterol 
from the macrophage PUFA supplementation has the potential to induce reverse 
holesterol transport from the atherosclerotic lesion.  Thus, in comparison to the foam 
cell enriched atherosclerotic lesion (A), treatment with PUFAs could reduce lesion area 
by inducing lysosomal and cellular cholesterol mobilization (B).  
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TG can mobilize cholesterol from macrophage foam cells which could ultimately lead to 
atherosclerotic lesion regression and remodeling. 
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